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ABSTRACT

ANALYSIS OF PROTEIN AND RNA
INTERACTIONS OF THE HIV-1 REV PROTEIN

by
John Francis

The HIV-1 Rev protein enters the nucleus via it’s nuclear localization
sequence/RNA binding domain and interacts with a =234 nt region of viral RNA,
termed the Rev Response Element (RRE), which is located in the env region of
unspliced and singly-spliced HIV-1 mRNA. The Rev nuclear export sequence
(NES) then mediates translocation of the viral transcript to the cytoplasm,
allowing for translation of viral structural genes and active virion formation. We
report identification of two yeast nucleopore proteins, NUP49 and NUP100, that
have been found to interact with Rev in vivo using the yeast two-hybrid system.
NUP49 and NUP100 contain GLFG repeats in their amino termini, but their
carboxyl termini diverge.

We have overexpressed and purified six-His tagged

versions of these nucleoporins and have demonstrated by in vitro assays that
their interaction with Rev in the two-hybrid system must be indirect. Additional
two-hybrid experiments have shown that Rev’s NES and the GLFG domains of
NUP49 and NUP100 are both required for their interaction. Based on these
experiments we propose that Rev-NUP interactions are important in Revmediated export of HIV-1 mRNA’s, but these interactions are most likely
mediated by another factor.

In vivo expression of the primary binding site of the RRE, known as the
Rev Binding Element (RBE), has previously been shown to inhibit HIV-1
replication in vivo. The specific interaction of such molecules with Rev is
necessary for their usefulness as therapeutics. We have found that RBE
aptamers evolved by SELEX interact specifically with a Rev RNA binding
domain peptide. In addition the linking of a ribozyme to an aptamer did not
affect its specific interaction with Rev protein. RBE aptamers and RBE
aptamer-ribozymes have the potential to function as anti-viral therapeutics. In
addition an RBE aptamer-ribozyme may enhance the ribozymes function by
facilitating colocalization with target HIV-1 mRNA. We also report the use of
novel templates for in vitro transcription. An RBE aptamer transcribed from
these templates was efficiently terminated by propane diol units, and gave rise
to a functional molecule in vitro. These templates have the potential to be used
in vivo for screening optimal anti-HIV RNA therapeutics.
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CHAPTER 1

INTRODUCTION

Although mammalian retroviruses were first discovered in 1951 by
Ludwik Gross (Gross, 1951), a human retrovirus (Human T-cell lymphotrophic
virus type I, HTLV-1) was not discovered until 1980 (Poiesz et al., 1980).
Research findings in 1984 implicated a new human retrovirus, HTLV-lll/human
immunodeficiency virus 1 (HIV-1) (Gallo et al., 1984), as the cause of acquired
immunodeficiency syndrome (AIDS) and stimulated a burst of extensive
research in the field of retrovirology. In this introduction I will expand on some
historical and current molecular biological findings on the HIV-1 replication
cycle, specifically on the HIV-1 Rev protein: the regulator of virion expression.
Rev has been shown to play a central role in viral production (for reviews
see Cullen & Malim, 1991; Rosen, 1991; Steffy & Wong-Staal, 1991; Cullen,
1992; Rosen, 1992). Rev shuttles between the nucleus and the cytoplasm,
increasing nucleocytoplasmic transport of HIV-1 mRNA (Kalland et al., 1994;
Meyer & Malim, 1994; Richard et al., 1994; D’Agostino et al., 1995; Stauber et
al., 1995; Szilvay et al., 1995; Wolff et al., 1995). The Rev protein binds to the
Rev Response Element (RRE) (Zapp & Green, 1989; Daefler et al., 1990;
Bohnlein et al., 1991; Huang et al., 1991; Malim & Cullen, 1991; Daly et al.,
1993a; Battiste et al., 1994; Jensen et al., 1995; Charpentier et al., 1997)
located in the envelope {env) region of unspliced and singly-spliced HIV-1
mRNA and transports this mRNA to the cytoplasm (Felber et al., 1989; Malim
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& Cullen, 1993), which allows translation of viral structural genes and active
virion formation (Feinberg et al., 1986; Sodroski et al., 1986; Rosen et al.,
1988; Arrigo & Chen, 1991; D’Agostino et al., 1992).
Rev has multiple functional domains including: nuclear/nucleolar
localization/RNA binding (Kubota et al., 1989; Malim et al., 1989b; Olsen et al.,
1990a; Venkatesh et al., 1990; Bohnlein et al., 1991) and multimerization in the
amino-terminus (Olsen et al., 1990a; Malim & Cullen, 1991;Madore etal.,
1994); and a activation/effector/multimerization domain (Malim et al., 1989b;
Venkatesh & Chinnadurai, 1990; Malim etal., 1991; Malim & Cullen, 1991;
McDonald et al., 1992; Bogerd & Greene, 1993; Madore et al., 1994) now
defined as a nuclear export signal at its carboxyl-terminus (Fischer et al., 1995;
for review see Gerace, 1995; Wen et al., 1995). Mutations within the nuclear
export signal result in a dominant negative phenotype (Malim et al., 1989b;
Mermer et al., 1990; Venkatesh & Chinnadurai, 1990). Trans-dominant Rev can
multimerize and bind RNA, but has no mRNA transport function (Olsen et al.,
1990a; Malim & Cullen, 1991; Meyer & Malim, 1994; Szilvay et al., 1995; Wolff et
al., 1995). Therefore, it has been hypothesized that this region is involved in
binding to cellular factors that facilitate Rev’s function (Malim et al., 1989b;
Olsen et al., 1990a; Venkatesh & Chinnadurai, 1990; Malim & Cullen, 1991;
Malim et al., 1991; McDonald et al., 1992; Bogerd & Greene, 1993; Madore et
al., 1994). The study of the Rev protein has implications for basic science as
well as clinical. As scientists learn about Rev, they will understand more about
eukaryotic RNA export as well as new possibilities for inactivating HIV-1.
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A. Acquired immunodeficiency syndrome

1. First American cases reported

In 1981 three articles were published (Gottlieb et al., 1981; Masur et al.,
1981; Siegaletal., 1981) describing evidence of a new acquired cellular
immunodeficiency. Nineteen homosexuals and/or drug users at University of
California Los Angeles medical center and eight hospitals in New York were
identified as having similar disease characteristics including: decreased
helper T cells and increased cytotoxic T cells, decreased mitogenic response,
weight loss, fever, Kaposi’s sarcoma, Pneumocystis carinii pneumonia,
mucosal candidiasis, chronic perianal ulcerative herpes simplex lesions,
multiple viral infections, increased opportunistic infections and more.
Gottlieb’s group supposed a high level cytomegalovirus (CMV)
exposure may have accounted for the occurrence of this immune deficiency,
since the patients’ disease state somewhat resembled primary CMV infection
in renal transplant patients undergoing iatrogenic immunosuppression. They
also proposed that the condition was potentially transmissible, since the
disease seemed to be found in homosexual men, and sexual transmitted
diseases were known to be common in homosexuals. Siegal’s group believed
the cause to be a viral infection, probably transmitted by the enteric route that
was causing a nation-wide epidemic among homosexuals. This was the
beginning of one of the most feared diseases of the decade, AIDS, for which
there is still no cure. Further research has shown that AIDS is
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nondiscriminating, infecting homo- and hetero-sexual, men and women, by
blood, as well as sexual contact (for review see Levy, 1993).
2. HIV-1 isolated as the causative agent in AIDS

There was some controversy (including allegations of scientific
misconduct) over who was first to isolate HIV-1 as the cause of AIDS. Most
sources now give the credit to Luc Montagnier, and report that Robert Gallo
had a good follow through. Both isolated a retrovirus from AIDS patients and
named it differently, lymphadenopathy-associated virus (LAV) (Barre-Sinoussi
et al., 1983; Barre-Sinoussi et al., 1985) and HTLV-III (Gallo et al., 1984;
Popovic et al., 1984). A third group isolated another virus from AIDS patients
and named it the AIDS-associated retrovirus (ARV) (Levy et al., 1984).
Eventually all three viruses were determined to be variants of the same virus
(Ratner et al., 1985) and it was decided to change their names to HIV (Coffin et
al., 1986).
Gallo’s group published a series of four articles in 1984 (Gallo et al.,
1984; Popovic et al., 1984; Sarngadharan et al., 1984; Schupbach et al., 1984)
discussing: 1) a new cell system called HT (human neoplastic T cell line) for
detecting, isolating, and continuous production of HIV;

2) frequent detection

and isolation of cytopathic retrovirus (HIV) from patients with AIDS and at risk for
AIDS; and 3) antibodies reactive with HIV in the serum of patients with AIDS.
Montagnier’s, Gallo’s and Levy’s work opened the door for detailed
immunological and molecular analyses of HIV, and was indeed a major step
towards defeating AIDS (for review see Vaishnav & Wong-Staal, 1991).
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3. Clinical hallmarks of AIDS

Once an individual becomes infected with HIV, it may take between
6 months to 7 or more years before they develop AIDS. AIDS classically is
associated with four main characteristics: 1) immune system dysfunction,
2) opportunistic infections, 3) neoplasms and 4) neurological complications. In
AIDS patients the immune system becomes severely impaired because of
decreased numbers of T helper cells. These cells are critical for activating and
inducing an effective immune response and, therefore, individuals lacking
them become susceptible to numerous opportunistic infections. Infections
commonly seen include those caused by parasites (Pneumocystis carinii
pneumonia), fungi (esophageal Candida albicans), bacteria (Mycobacterium
avium-intracelluare complex tuberculosis) and viruses (Cytomegalovirus
retinitis). Along with increased infections, these patients also have an increase
chance of developing cancer. The cancer types include: Kaposi’s sarcoma,
lymphomas of the brain and non-Hodgkin’s lymphoma. The last characteristic
frequently seen is neurological impairment. AIDS Dementia complex, HIV
encephalopathy and Toxoplasmosis of the brain are some of the diseases
encountered (Jawetz et al., 1991).
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B. The HIV-1 Rev protein

1. rev gene discovery

With HIV isolated and implicated as the cause of AIDS, extensive
research resulted in this area (for reviews see Haseltine, 1988; Vaishnav &
Wong-Staal, 1991). Molecular biological techniques led to the discovery of
many genes involved in the virus replication cycle, including gag, pot, env, tat,
nef and vif, by 1986, just two years after HIV was discovered. Sodroski et al.
(1986) reported a seventh gene necessary for viral replication that acted posttranscriptionaly to relieve negative regulation of the mRNA for the structural
proteins. They called this gene anti-repression frans-activator (art).
Feinberg et al. (1986) identified the same gene. Mutations in it led to a
decrease in 9 kb (gag and pol) and 4 kb (env) mRNA expression, while 2 kb (tat
and nef) mRNA expression increased, they called this gene frans-acting
regulator of splicing (trs). Both groups were actually working with mutations in
the tat gene and demonstrated that exogenous Tat complements the effect of
various tat mutations. However, they found that the effects of some mutations
in the tat gene were not relieved by exogenous Tat. The tat gene partially
overlaps another gene essential for virus production, the art/trs gene.
With different groups isolating the same genes and naming them
differently it became apparent that there would be a need for a standard
nomenclature. Gallo et al. (1988) published an article describing such a
standard for many of the genes identified in HIV up to 1988. As a result, the
Art/Trs protein was renamed Rev (regulator of expression of virion proteins).
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2. Rev protein domain analysis

Rev protein is 116 amino acids in length, and was first expressed in
bacteria as a 20 kd protein by Goh et al. (1987), and subsequently expressed in
mammalian COS cells as a 19 kd protein by Knight et al. (1987). Both papers
showed that the expressed protein was immunoreactive with sera from HIV
infected patients. Cullen et al. (1988), used immunohistochemistry and
subcellular fractionation to demonstrate that the Rev protein expressed in COS
cells was localized to the nucleus. Further research soon demonstrated that
Rev was located predominantly in the nucleolus (Felber et al., 1989; Kubota et
al., 1989; Venkatesh et al., 1990).
Malim et al. (1989b) mutated a region of basic amino acids near the
amino terminus and found that the altered Rev was then preferentially localized
to the cytoplasm instead of the nucleus. These mutations defined Rev’s
nuclear localization sequence (NLS). Perkins et al. (1989), Kubota et al.
(1989), and Venkatesh et al. (1990) showed that p-galactosidase/Rev-NLS
fusion proteins were targeted to the nucleus and nucleolus, correlating with
Malim’s work (1989b).
Malim and Cullen (1991) also showed that between two and eight
molecules of Rev interacted with the RRE in vitro. Interestingly, mutations of
the amino-terminal and carboxyl-terminal regions flanking the basic NLS
resulted in a decrease in the number of molecules interacting with the RRE in
vitro and in vivo, and also a decrease in Rev activity. These regions defined a
functional multimerization domain, with critical residues located between
amino acids 15 and 60 (Olsen et al., 1990a; Malim & Cullen, 1991; Madore et
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al., 1994; Thomas et al., 1998). Daly et al. (1993b) published that deletion of
amino acids in the carboxyl-terminal region of Rev beyond the activation
domain also affect multimerization in vitro. Therefore, multiple regions of Rev
appear to be involved in multimerization. It was also determined that mutations
in the Rev NLS inhibited binding to the RRE. This result demonstrated a dual
role for the amino terminal basic motif (aa 35-50): nuclear/nucleolar localization
and RNA binding (Malim et al., 1989b; Malim et al., 1990; Olsen et al., 1990a;
Malim & Cullen, 1991). Heaphy et al. (1991) and Malim and Cullen (1991)
believe that a single Rev molecule binds the RRE first in stem loop 2B, then
other Rev molecules multimerize with bound Rev on the RRE. Olsen et al.
(1990a) contradicted that hypothesis with a suggestion that multimerization is a
prerequisite for binding to the RRE. However, Cole et al. (1993) provided
evidence to support the sequential binding hypothesis (Heaphy et al., 1991;
Malim & Cullen, 1991). Although high concentrations of Rev can oligomerize in
solution in the absence of RRE, they showed that Rev can interact with the RRE
at low concentrations when it is predominantly in monomeric form.
Malim et al. (1989b) reported that substitution mutations in a stretch of
leucine residues within Rev’s carboxyl terminus resulted in a dominant
negative phenotype. Malim and Cullen (1991) subsequently showed that this
region, located between aa 75 and 83, was not involved in RNA binding or
multimerization in vitro, yet it was crucial for in vivo Rev function. It therefore
seemed plausible that this area of Rev interacted with cellular proteins that
facilitated Rev action, and as a result it was called the Rev activation domain.
Further research, however, showed that deletion of this domain affects RRE
dependent Rev-Rev interactions in vitro (Daly et al., 1993b). Substitution
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mutants in the activation domain inhibit multimerization in vivo (Bogerd &
Greene, 1993; Madore et al., 1994). Since these substitution mutants have no
affect on multimerization in vitro (Malim & Cullen, 1991; Daly et al., 1993b), yet
they inhibit multimerization in vivo (Bogerd & Greene, 1993; Madore et al.,
1994), it has been proposed that one function for the activation domain may be
to interact with a cellular factor that facilitates bridging interactions between Rev
proteins and allows for functional and stable multimerization on the RRE
(Bogerd & Greene, 1993; Madore et al., 1994).
Cochrane et al. (1989) showed that Rev is a phosphoprotein but
phosphorylation was shown to be dispensable for its function. Meggio et al.
(1996) determined that Rev can be phosphorylated by protein kinase CK2 and
MAP kinase. They found that mutations in the amino-terminus that decreased
Rev’s activity, led to an increase in Rev’s phosphorylation by CK2. Based on
these results they speculated that phosphorylation by CK2 may play a role in
Rev regulation. Pouts et al. (1997) reported that protein kinase C
phosphorylation of Rev within it’s carboxyl-terminal region flanking the basic
NLS promotes a conformational change in Rev. This conformational change
enhances the efficiency of RNA binding by the Rev protein. The biologic role of
Rev’s phosphorylation is still in question. Further research in this area may
help to clarify the effect of phosphorylation on Rev activity in vivo.

3. Nucleocytoplasmic shuttling of Rev

Numerous articles published in about a years time described the ability
of Rev to shuttle between nuclear and cytoplasmic compartments (Kalland et
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al., 1994; Meyer & Malim, 1994; Richard et al., 1994; D’Agostino et al., 1995;
Stauber et al., 1995; Szilvay et al., 1995; Wolff et al., 1995). I have chosen to
discuss one of the first by Meyer and Malim (1994). Previous work had shown
that Rev was localized predominantly in the nucleus (Cullen et al., 1988; Felber
et al., 1989; Kubota et al., 1989). This led to the belief that Rev was confined
there. Meyer’s results showed that Rev was not confined to the nucleus but
was in a state of constant flux between the nucleus and the cytoplasm in an
energy dependent manner. They also showed that inactivation of the leucine
rich activation domain generates mutant Rev proteins that not only fail to induce
the nuclear export of viral transcripts but are also unable to enter the cytoplasm.
They proposed that Rev activates viral mRNA transport by binding to the mRNA
and translocating with them to the cytoplasm. In addition, their results were the
first to identify a peptide sequence that was important for nuclear export.

4. Rev utilizes specific export pathways

Another paper illustrating the importance of Rev’s activation domain was
by Fisher et al. (1995). They showed that bovine serum albumin molecules
fused to Rev’s activation domain (BSA-AD) are exported from the nucleus in an
energy dependent manner. Injection of this fusion protein into Xenopus
oocytes inhibited wild type Rev’s ability to transport RRE-containing RNA. The
BSA-AD fusion protein competed with Rev for access to the nuclear export
machinery, thereby, inhibiting its function. BSA fused to a mutated AD did not
inhibit wild type Rev’s function.
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The ability of BSA-AD fusion proteins to affect the export of non-Rev
dependent mRNA was also studied. Radiolabeled mRNA and BSA-AD
proteins were coinjected into Xenopus oocytes with the expectation of seeing a
decrease in export of the mRNA. To their surprise they saw no affect on mRNA
transport. However, when they looked at the transport of SSrRNA and selected
snRNA’s they found that BSA-AD proteins could inhibit their export. Thus they
concluded that the Rev activation domain constitutes a nuclear export signal
(NES) that redirects RRE-containing viral RNA’s to a non-mRNA export
pathway.
Murphy and Wente (1996), on the other hand, identified a yeast protein,
Gle1, that utilizes a NES that is homologous to the NES in Rev to transport
mRNA. Mutation of the Gle1 NES led to a decrease in nuclear export of
polyadenylated RNA in yeast. In an attempt to gain a clearer understanding of
the RNA pathways mediated by leucine rich export signals, Pasquinelli et al.
(1997) repeated some of the experiments performed by Fisher with
modifications. They found that human serum albumin fused to the Rev NES
inhibited the transport of snRNA, SSrRNA and mRNA, but not tRNA in Xenopus
oocytes. They also showed that an excess of Rev’s NES competed for shared
cellular factors used for export of snRNA, SSrRNA and mRNA. Their results
together with Wente’s showed that leucine-rich export signals, as seen in the
Rev protein, are indeed used in mRNA export within the cell. Therefore, HIV
uses the Rev protein to transport its mRNA along a normal mRNA export route.
Pasquinelli et al. (1997) reasoned that the difference between their results and
that of Fisher et al. (1995) was the length of time used for the conjugation of
serum albumin to NES peptides. Fisher’s longer chemical crosslinking times
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allowed for larger protein aggregates to form. This may have affected the ability
of the conjugated serum albumin NES proteins to interact with a mRNA export
receptor.

5. Rev introduces a new class of nuclear export signals

Although much has been learned about nuclear import and nuclear
localization sequences (for review see Pante & Aebi, 1996), much less is
known about nuclear export and protein sequences involved in export (for
review see Nakielny & Dreyfuss, 1997). Recent studies of Rev as a prototype of
proteins that contain nuclear export signals, have led to the beginning of the
delineation of the export pathway (for reviews see Gerace, 1995; Nigg, 1997).
Multiple proteins that contain NES domains homologous to Rev’s have now
been discovered (Fig. 1). These proteins are involved in protein transport as
well as RNA transport and are found in yeast (Murphy & Wente, 1996; lovine &
Wente, 1997; Segref et al., 1997), frogs, toads (Fridell et al., 1996c), mice,
rabbits (Zolotukhin & Felber, 1997) and humans (Fridell et al., 1996a; Fridell et
al., 1996b; Zolotukhin & Felber, 1997). Therefore, their function appears to be
important and conserved.
Proteins containing a NES can function to transport themselves or other
molecules of RNA or protein. All of the viral proteins identified to date that bear
an NES are involved in viral RNA transport. These proteins include: Rev
proteins from HIV-1/HIV-2 , caprine arthritis encephalitis virus (CAEV) (Bogerd
et al., 1995), visna-maedi virus (VMV), equine infectious anemia virus (EIAV)
(Meyer et al., 1996), feline immunodeficiency virus (FIV) and simian
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immunodeficiency virus (SIVmac239) (Kim et al., 1996); Rex proteins from
HTLV-1/HTLV-2 (Bogerd et al., 1996) and the adenoviral E4-34KD protein
(Dobbelstein et al., 1997). NES-containing proteins like human transcription
factor MIA (TFIIIA, Fischer et al., 1995); Fragile X mental retardation protein
(FMRP, Eberhart et al., 1996; Fridell et al., 1996a), yeast Gle1 (Murphy & Wente,
1996) and Mex67p (Segref et al., 1997) have also been implicated in RNA
transport. Interestingly, X. laevis TFIIIA has been shown to be involved in 5S
RNA export (Fridell et al., 1996c). The Rev NES is known to inhibit 5S RNA
export, showing that Rev probably competes with TFIIIA for one or more
common export factors and/or for a putative nuclear export receptor (Fischer et
al., 1995). Other proteins that bear an NES can export themselves or cargo
molecules. Cyclic AMP-dependent protein kinase inhibitor (PKI) exerts its
inhibitory function on the kinase catalytic subunit (C) by binding to it and
removing it from the nucleus, thus blocking access to its nuclear target (Wen et
al., 1994; Wen et al., 1995). Kap95, a yeast protein homologous to
importin p/karyopherin |3, has a NES that may allow the protein to transport
itself back to the cytoplasm after it has imported cargo into the nucleus (lovine
& Wente, 1997). RanGTPase binding protein 1 (RanBPI) is a NES containing
protein that interacts with RanGTP (Pasquinelli et al., 1997), a GTPase that is
essential for all export cargo (Izaurralde et al., 1997; Richards et al., 1997). It is
believed that the interaction between RanBPI and RanGTP may help to direct
RanGTP towards the export machinery where its presence is crucial
(Zolotukhin & Felber, 1997). IkB, the inhibitor of NFkB, is a NES protein that is
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now believed to exert an inhibitory effect by inducing the rapid export of NFkB to
the cytoplasm, thereby preventing NFkB from performing its nuclear function
(Fritz & Green, 1996).
Nuclear export is a saturatable, temperature and energy dependent
process (for review see Fabre & Hurt, 1994). It is mediated by NES proteins of
which Rev is a prototype of one class (for review see Nakielny & Dreyfuss,
1997). The Rev type NES is made up of a domain that is rich in leucine
residues (I_1 PPL2ERL3TL4) (Fischer et al., 1995). An analysis of homologous
NES and functional NES mutants shows that valine, methionine and isoleucine
can substitute for leucines at positions one and two. Valine and isoleucine can
also substitute for leucine at position four. These findings emphasize that the
presence of large hydrophobic residues at these positions are important
(Fischer et al., 1995; Bogerd et al., 1996; Kim et al., 1996; Zolotukhin & Felber,
1997). Mutations at critical leucine residues inhibit export and result in
dominant negative mutants, an example of which is the Rev M10 mutant (Malim
et al., 1989b). The spacing between the hydrophobic residues varies (Bogerd
et al., 1996). A 2:2:1, spacing is found in Rev, human and
B. americanusTF\\\A (Fischer et al., 1995), Mex67p (Segref et al., 1997) and a
3:2:1 spacing is found in IkB (Fritz & Green, 1996), PKI and RanBPI (Zolotukhin
& Felber, 1997). Most Rev-like NES proteins found to date have a consensus
sequence of (Leu/lleA/al/Met)-X1 ^-(Leu-Val-Met)-X2-4-(Leu)-X-(Leu/lleA/al)
(Fischer et al., 1995; Bogerd et al., 1996; Kim et al., 1996; Dobbelstein et al.,
1997; lovine & Wente, 1997; Zolotukhin & Felber, 1997), except for the EIAV and
FIV Rev proteins which are atypical (Kim et al., 1996).
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Import receptors are crucial to the nuclear import of proteins. The
receptor importin alpha interacts with NLS signals, and importin beta docks the
NLS cargo proteins to the nuclear pore, allowing for import (Radu et al., 1995;
Rexach & Blobel, 1995; for review see Pante & Aebi, 1996). By comparison,
one would expect an NES protein to function in a similar manner, by interacting
with a NES receptor and possibly a cofactor that could dock the NES protein to
the nuclear pore.
C. The Rev Response Element

1. RRE discovery

Rev originally was shown to be involved with increasing expression of
the 9 kb unspliced mRNA {gag and pol) and 4 kb (env) mRNA species, while
decreasing production of the 2 kb mRNA species {tat, rev, and nef). How Rev
exerted this effect on mRNA was not known (Feinberg et al., 1986). Rosen et
al. (1988) and Dayton et al. (1988) showed that sequences in the gag, po/and
env region exert a negative effect on gag, pol and env expression. Other
sequences in env are necessary for the Rev protein to relieve this negative
effect. These sequences were called c/s-acting repression sequences (CRS)
and c/s-acting anti-repression sequences (CAR), respectively (for review see
Haseltine, 1988). Since only the 9 kb and 4 kb mRNA species included these
sequences, they were the only ones that responded to Rev.
After Malim et al. (1989a), and Felber et al. (1989) described the CAR
region as being a Rev Responsive Element (RRE) of 234 nt, RRE replaced the
earlier designation in subsequent publications. Felber showed that Rev
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increased the stability of unspliced 9 kb and singly-spliced 4 kb viral mRNA,
while it does not affect the stability of the multiply spliced 2 kb viral mRNA’s.
Malim reported that the response to Rev is fully maintained when the RRE is
relocated to other exonic or intronic locations within env, but is ablated by
inversion. Even though this initial work was done to show that Rev needs the
RRE to function, Rev was not actually shown to interact with the RRE. Zapp et
al. (1989) and Daly et al. (1989) were the first to show sequence-specific
binding in vitro of Rev to the RRE. Their work helped to clarify the mechanism
with which Rev enhanced export of viral mRNA, by specifically binding to a
region within env.

2. Functional analysis of the RRE

The RRE was shown by Malim et al. (1989a) and Dayton et al. (1989) to
be a 234-250 nt multiple stem-loop structure. This structure contains one
major stem (stem 1) and four stem-loops branching from the main stem
(stem-loops 2-5). Stem-loop 2 can further be subcategorized into 3 regions:
2A, 2B, and 2C (Bartel et al., 1991). Olsen et al. (1990b) and Huang et al.
(1991), determined the regions of the RRE important for Rev function through
deletion mutation analysis. Deletions of stem-loop 5 showed function
equivalent to wild type, while deletions of stem-loops 2C or 4 resulted in
reduced function. Mutations in stem-loop 3 showed increased (Huang et al.,
1991) or decreased (Olsen et al., 1990b) activity. Deletion of stem-loop 2 or 2B
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ablated Rev function and in vitro Rev binding. Therefore, in the context of the
RRE, stem-loop 2B was considered the primary determinant of Rev interaction
and Rev responsiveness in vivo.
Huang et al. (1991) determined the minimal regions of the Rev
Response Element necessary for Rev-dependent function. Stem-loop 2 alone,
separate from the other sequences of the RRE, allowed for the transport
function of Rev, albeit at reduced levels. Two stem-loop 2 regions in tandem,
however, were found to function as well as the wild type RRE. Stem-loop 2B,
without any other RRE sequences, could not support Rev transport function.
Mobility shift assays have shown that stem-loop 2B interacts with one Rev
molecule, while three Rev molecules interact with stem-loop 2 (Cook et al.,
1991; Kjems et al., 1992). This data supports the notion that two to three Rev
proteins bound to an RNA molecule can allow for RNA transport. Indeed,
researchers have shown that mutations in the carboxy-terminus of Rev
decrease in vitro Rev multimerization, allowing for only two to three Rev
proteins to interact with the RRE, are still capable of supporting Rev function in
vivo (Daly et al., 1993b).
Based on compensatory mutation studies it was shown that Rev binding
to stem-loop 2B was dependent on secondary structure and not sequence
(Olsen et al., 1990b; Huang et al., 1991). Bartel et al. (1991) however, reported
that some sequence was necessary for Rev binding. Rev specifically
recognizes a non-canonical Watson-Crick base pair in a bulged region directly
adjacent to stem-loop 2B. This G:G base pair, is essential for Rev binding and
can be replaced only with A:A, if binding is to occur. They proposed that the G:G
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base pair distorts the sugar-phosphate backbone of viral RNA and that this
distortion is critical for recognition by Rev (for review see Green, 1991).
D. Rev mediated HIV-1 mRNA transport

1. Rev facilitates mRNA access to export machinery
The exact mechanism by which Rev facilitates nucleocytoplasmic export
of unspliced and singly-spliced viral pre-mRNA is still not completely
understood. Three theories have been presented to explain this phenomenon.
First, some believe that Rev exerts a direct role in promoting nucleocytoplasmic
export of viral pre-mRNA (Malim & Cullen, 1993; Fischer et al., 1994; Meyer &
Malim, 1994). Evidence for this was seen in the experiments of Fisher et al.
(1994) where it was shown that mRNA lacking intron sequences and functional
splice sites but containing an RRE can be efficiently exported from the nucleus
oiXenopus laevis oocytes in a Rev-dependent manner. This result
demonstrated that Rev could act directly at the level of export, independent of
any inhibitory effect that it may exert on the splicing of pre-mRNA. Malim and
Cullen (1993) showed that although Rev transports unspliced and singlyspliced mRNA to the cytoplasm in T cells, the expression of fully spliced mRNA
remains unchanged. This result would not be expected if Rev caused a
decrease in splicing of viral mRNA that led to mRNA export. Meyer and Malim
(1994) showed that Rev was not confined to the nucleus, but shuttled
constantly between nuclear and cytoplasmic compartments. Dominant
negative mutants of Rev were not exported and failed to induce export of viral
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mRNA. They proposed that Rev induces the transport of viral mRNA by binding
directly to the mRNA and translocating with it to the cytoplasm.

2. Rev induces mRNA transport by inhibition of splicing

A second theory is that Rev might block splicing of viral mRNA by
interacting with proteins involved in splicing. This interaction would lead to
dissociation of viral mRNA from splicing components and/or inhibition of
formation of the splicing complex (Chang & Sharp, 1989; Chang & Sharp, 1990;
Kjems & Sharp, 1993).

Supporting evidence for this theory is seen in the data

of Kjems et al. (1993), showing that Rev blocks U4, 1)5, and U6 from entering
the splicesome complex. It partially blocks U2, but has no effect on the binding
of U1. Their results demonstrate that Rev can specifically inhibit splicing in
vitro, possibly allowing for export of unspliced viral pre-mRNA. The mechanism
of this inhibition may be mediated through Rev’s interaction with YL2/p32, a
protein believed to be involved in splicing, and known to interact with the serinearginine-rich splicing factor ASF/SF2 (Luo et al., 1994; Tange et al., 1996).
ASF/SF2 enhances U1 snRNP’s binding to pre-mRNA, and interacts with
proteins within U1 and U2 snRNP’s. Therefore, ASF/SF2 is believed to be
involved in bridging the interaction of U1 snRNP’s at the 5’ splice site with U2
snRNP’s at the 3’ splice site (Wu & Maniatis, 1993; Kohtz et al., 1994).
ASF/SF2 has been shown to interact with the RRE in a Rev dependent manner
(Powell et al., 1997). The presumed indirect interaction of Rev with ASF/SF2
through p32, and ASF/SF2’s dependence on Rev to bind to the RRE may inhibit
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U4, U5, and U6 snRNA from entering the splicing complex. This inhibition
would be by blocking the bridging of U1 and U2 snRNP’s necessary for
subsequent splicesome assembly (Powell et al., 1997).
I personally believe in a third theory that suggests Rev might inhibit
splicing of viral pre-mRNA and directly transport the pre-mRNA. The first two
theories might not be mutually exclusive. Further research in this area may
help to delineate the exact mechanism.

E. Rev interacts with cellular proteins

1. B23
Many authors speculated that Rev function was mediated by interaction
with cellular proteins (Malim et al., 1989b; Olsen et al., 1990a; Venkatesh &
Chinnadurai, 1990; Malim & Cullen, 1991; Malim et al., 1991). Fankhauser et
al. (1991) was first to identify a putative interacting factor. Nuclear extracts from
HeLa cells, rat liver cells or chicken liver cells were applied to a Rev affinity
column. All extracts tested allowed for purification of a 38 KD protein that was
found to be B23. The interaction between B23 and Rev was determined to be
specific, however the interaction could be dissociated by the presence of the
RRE.
B23 is a multifunctional phosphoprotein (Mamrack et al., 1977; Chan et
al., 1990) also called N038 (Peculis et al., 1992), Numatrin (Feuerstein et al.,
1990) and Nucleophosmin (Chan et al., 1990). The protein is highly conserved
among various species (Chang et al., 1989), and exists as two isoforms, B23.1
and B23.2, due to alternative splicing (Chang et al., 1990). B23 is located
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primarily in the granular and dense fibrillar components of the nucleolus
(Biggiogera et al., 1989). Within the nucleoli it is found in association with
preribosomal particles (Prestayko et al., 1974; Yung et al., 1985), specifically as
part of the precursor of the large ribosomal subunit. However, B23 is not
present in the mature ribosome (Yung et al., 1985). B23 has been shown to
bind RNA (Michalik et al., 1981; Dumbar et al., 1989; Wang et al., 1994), and
have intrinsic ribonuclease activity (Herrera et al., 1995). Therefore, it is
possible that it may be involved in ribosome biogenesis and possibly rRNA
processing.
B23 contains a bipartite NLS in its central region as well as a region
important for nucleolar localization in its C-terminus (Peculis et al., 1992). It
had previously been reported that B23 was located primarily in the nucleolus
(Prestayko et al., 1974; Michalik et al., 1981) and that it shuttled between the
nuclear and cytoplasmic compartments (Borer et al., 1989). Borer et al. (1989)
hypothesized that B23 was involved in the nuclear import of ribosomal proteins
and possibly nuclear export of preribosomal particles. Fankhauser et al.
(1991) rationalized that B23 may also be involved in Rev’s transport. B23’s
interaction may assist Rev protein in entering the nucleus where the presence
of the RRE could dissociate their interaction. Rev could then direct the
transport of the RRE bearing RNA to the cytoplasm. B23 may also be involved
in Rev’s predominant location within the nucleolus. Rev bound to B23 may be
held in the nucleolus until HIV-1 mRNA is available to be transported.
Rev’s ability to colocalize with B23 was studied by Miyazaki et al. (1995).
They used immunofluorescence techniques in COS7 cells to show that Rev
was localized in the dense fibrillar areas and granular components in the
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nucleolus, these regions are involved in RNA processing and assembly of
ribosomal subunits respectively. B23 was found to partially overlap the
distribution of Rev. Overexpression of Rev resulted in nucleolar ballooning,
with accumulations of B23 and rRNA, and dispersing of nucleolar structures
into patches. The authors hypothesized that overexpression of Rev may
interfere with the nuclear export of ribosomes by functional inhibition of B23.
This inhibition could be direct by binding of Rev to B23 or indirect by Rev
interaction with rRNA, thereby inhibiting processing and subsequent ribosomal
export.
Szebeni et al. (1995) determined that B23 could interact specifically with
peptides based on the Rev NLS. Rev NLS peptides were found to interact 10
times stronger with B23 than peptides derived from the NLS of the SV40 T
antigen. Interestingly when B23 was phosphorylated by casein kinase II its
interaction with both NLS peptides was enhanced 2-fold. Two highly conserved
acidic regions of B23 (Chang et al., 1989) have been shown to be involved in
the interaction with nucleolar localization sequences (Adachi et al., 1993), it is
within one of these acidic stretches that phosphorylation of a serine residue by
casein kinase II occurs (Chan et al., 1990).
Further research by Szebeni et al. (1997) showed that B23 actually
stimulates nuclear import of Rev protein. They found that the presence of B23
enhanced Rev protein or SV40 T antigen NLS-BSA conjugates transport into
isolated rat liver nuclei by 2-fold and that mutation of the bipartite NLS of B23
ablated the stimulatory affect. An important find was that phosphorylated B23
(by casein kinase II) resulted in a 4 to 5-fold increase in nuclear import. B23
mediated import was also found to be energy dependent, and blocked by anti-
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p97 antibodies. p97, (Delphin et al., 1997), also known as importin p (for
reviews see Gorlich et al., 1996; Gorlich, 1997) and karyopherin (3 (Moroianu,
1995), has been shown to be an essential component of the nuclear import
machinery specifically involved in docking NLS bearing cargo to phenylalanine
and glycine repeat containing nucleoporins. This data suggests that B23 may
function as an accessory factor in the nuclear import of Rev and normal cellular
proteins bearing NLS. The data also supports the notion that B23’s import role
may be regulated by phosphorylation.

2. YL2/p32

One theory for Rev function is that Rev is able to transport unspliced and
singly-spliced viral mRNA by inhibition of splicing. If that is the case one might
expect Rev to interact some how with splicing components. In an effort to find
Rev interacting factors Luo et al. (1994) screened a murine cDNA library with
the yeast two-hybrid system. Out of 100,000 clones they identified a Rev
binding protein YL2, which was found to be homologous to human p32. p32’s
function is still in question, but it copurifies with an alternative splicing factor
known as ASF/SF2 (Krainer et al., 1990; Krainer et al., 1991). YL2 was found to
interact with the Rev AD mutant M10, but not with Rev mutated in its basic
domain (Luo et al., 1994). Therefore the basic domain appears to be essential
for the interaction. Interestingly, the basic domain has also been found to
inhibit splicing in vitro (Kjems & Sharp, 1993). YL2 was also found to affect Rev
function. Expression of YL2 in CV1 cells containing Rev and a Rev-dependent
CAT reporter gene allowed for a 31 fold increase in Rev-dependent CAT
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expression. In addition antisense to YL2 was found to inhibitory to Revdependent CAT expression (Luo et al., 1994). Luo et al. (1994) hypothesized
that since ASF/SF2 has been implicated in committing pre-mRNA to be spliced
(Fu, 1993), Rev’s ability to inhibit splicing may be through indirect affects on
ASF/SF2, mediated by p32.
Tange et al. (1996) addressed the question of whether Rev bound to the
RRE could interact with p32. Their results showed that glutathione-sepharose
beads could pull down radiolabeled RRE or RBE in the presence of GSTp32
only when Rev or Rev basic domain peptide was present. Their mobility shift
assays however showed conflicting results. High mobility Rev-RRE complexes
were found to be inhibited by the presence of p32. The authors suggested that
the ternary complex present in the precipitation experiments are probably
unstable in the shift assays. It was also determined that exogenous p32
relieved the block in splicing caused by the basic domain of the Rev protein.
This could be because Rev is sponged up by exogenous p32, or Rev’s binding
to the RRE is inhibited by interaction with p32. Clearly further research needs
to be done to elucidate the role of p32 in Rev function.
ASF/SF2 is part of the SR family of splicing factors, which tend to have
one or two RNA recognition motifs (RRM) and multiple arginine-serine repeats
(Fu et al., 1992). Extracts deficient in all SR proteins are inactive in splicing
assays. Adding an excess of any SR family member reconstitutes splicing
activity. p32, however was not able to reconstitute splicing in these extracts, nor
affect the activity of ASF/SF2, therefore it’s exact role in splicing has not been
defined (Krainer et al., 1991). Powell et al. (1997) demonstrated that ASF/SF2
binds the RRE in a Rev-dependent manner in vitro, and its expression was
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shown to inhibit Rev function and HIV replication in vivo. Mutation of ASF/SF2’s
N-terminal (RRM) blocked this action. These authors believe that Rev’s
inhibition of splicing involves Rev’s recruitment of ASF/SF2 to the RRE, and that
Rev’s inhibition is overcome by increasing levels of ASF/SF2 in the cell.
Cellular and viral factors have been found to interact with p32. p32 is
synthesized as a 282 aa pro-protein that is subsequently processed to 209 aa
(Honore et a!., 1993). It contains multiple potential phosphorylation sites and is
known to bind hyaluronic acid as a homodimer (Deb & Datta, 1996). p32
interacts with the RS domain of the inner nuclear membrane lamin B receptor
(LBR) (Simos & Georgatos, 1994). Phosphorylation of the RS domain by LBR
kinase or its deletion abrogates interaction with p32 (Nikolokaki et al., 1996).
Simos and Georgatos (1994) speculate that since p32 interacts with splicing
factors and the nuclear membrane, it may serve as a bridge between them.
Evidence supporting the possibility of a bridge is seen in immunoelectron
microscope studies that showed an SR splicing factor SC35, known to copurify
with ASF/SF2 (Fu et al., 1992), in contact with the nuclear lamina of the nuclear
envelope (Spector et al., 1991). Finally, the herpes simplex virus 1 ORF P
protein, believed to be involved in latency, was shown to colocalize with splicing
factors and to interact with p32 (Bruni & Roizman, 1996). Randall and Roizman
(1997) showed that ORF P protein is important for decreasing expression of
viral proteins made from spliced RNA, and speculate this function may be
directed through p32.
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3. elF-5A

In an effort to identify a cellular interacting partner of Rev, Ruhl et al.
(1993) used a Rev AD peptide in crosslinking experiments with total nuclei or
the nuclear envelope fraction of HeLa cells. Competition experiments identified
a 19 KD protein as a specific interacting partner of the Rev AD. Following
protein purification and partial sequencing, the protein was identified as the
eukaryotic initiation factor 5A (elF-5A).
Rev function is affected by elF-5A and elF-5A mutants (for review see
Bevec & Hauber, 1997). Using Northern and Southern analysis, Ruhl et al.
(1993) determined that elF-5A RNA was undetectable in Xenopus oocytes.
Using microinjection into Xenopus oocytes, they found that Rev was unable to
affect the expression of a Rev-dependent CAT reporter gene unless the elF-5A
protein or gene was coinjected.

Bevec et al. (1996) found that coinjection of

Rev with elF-5A into the nuclei of HeLa cells enhanced Rev export. They also
showed that elF-5A is able to interact with Rev while it is bound to the RRE, but
not the Rev AD mutant M10. Non-functional elF-5A mutants that could bind to
the Rev/RRE complex were found to dramatically inhibit Rev function and HIV-1
replication in human T cells (Bevec et al., 1996; Junker et al., 1996). Ruhl et al.
(1993) also determined that elF-5A antisense in COS cells blocked Revdependent CAT expression.
elF-5A, formerly known as elF-4D (Kang et al., 1993), is a protein
containing 154 aa, with a molecular weight of approximately 17 KD (SmitMcBride et al., 1989a; Park, 1989). The protein is conserved in all eukaryotes

31
(Klier & Lottspeich, 1992) and has been detected within the nucleus (Ruhl et
al., 1993; Klier et al., 1995) and the cytoplasm (Ruhl et al., 1993; Klier et al.,
1995; Shi et al., 1996). elF-5A is known to be phosphorylated at serine
residues (Kang et al., 1993), and is the first protein to be identified as having
the unique amino acid hypusine, formed by post-translational modification of a
lysine residue (Park, 1989; Hershey et al., 1990).
The presence of hypusine is crucial for the function of elF-5A. elF-5A is
believed to be involved in forming the first peptide bond (Flershey et al., 1990).
Hypusinated elF-5A (but not unhypusinated) can initiate protein synthesis in
vitro (Park, 1989; Smit-McBride et al., 1989b). The presence of the hypusine
modification was also found to be essential for stimulation of protein synthesis
in vivo (Smit-McBride et al., 1989b) and Saccharomyces cerevisiae cell growth
(Schnier et al., 1991). elF-5A depleted yeast cells allowed for the continuation
of protein synthesis at a level 70% of wild type, with only small changes in
polysome profiles. Therefore elF-5A is probably involved in the translation of
some, but not all mRNAs (Kang & Hershey, 1994). Indeed, Hanauske et al.
(1995), using a system to reversibly suppress hypusine formation, found
certain mRNAs depart from or arrive at the polysomes dependent upon the
presence or absence of hypusine in cells, demonstrating that hypusinated elF5A increases polysomal utilization of specific mRNAs. Liu et al. (1997) found
by motif analysis that elF-5A has a region that resembles an RNA-binding motif
in its amino terminus. They showed that hypusinated elF-5A (and not the
unhypusinated form) was able to interact with the RRE, U6 snRNA or a RevRBE complex. They believe that elF-5A may play a role in RNA processing as
well as protein synthesis.
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Based on the above described functions, it has been proposed that
hypusinated elF-5A targets Rev/RRE containing HIV-1 mRNAs to the
translational apparatus (Ruhl et al., 1993; Katahira et al., 1995). Congruent
with this hypothesis, Rev has been shown to promote polysomal association
and enhance translation of HIV-1 RRE containing mRNAs. Therefore Rev’s
function may extend beyond inhibition of splicing and/or nucleocytoplasmic
transport to promoting cytoplasmic localization and efficient translation of RRE
containing mRNAs (Arrigo & Chen, 1991; D’Agostino et al., 1992). It is
conceivable that this latter function of Rev may be mediated by elF-5A.
Although there appears to be numerous evidence supporting elF5A/Rev interaction, and a role for elF-5A in Rev function, these results have
been called into question. Bogerd et al. (1995) claim that they were unable to
demonstrate an interaction between elF-5A and Rev using various genetic
assays. Liu et al. (1997) showed that elF-5A is able to interact with the RRE in
the absence of Rev. Shi et al. (1996) determined that elF-5A can be detected in
Xenopus oocyte extracts and Fischer et al. (1994) showed that Rev could
function in Xenopus oocytes without exogenous elF-5A. These conflicting
findings illustrate that more experiments need to be carried out to better
delineate the role elF-5A plays in the HIV-1 life cycle.

4. Prothymosin a

Using affinity chromatography Kubota et al., (1995) identified
prothymosin a as a potential Rev interacting factor. Rev-AD columns were
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used to isolate Rev binding proteins from MOLT-4 whole cell extracts. The
major binding protein was one of 18 KD, that was subsequently identified as
prothymosin a.
The true function of prothymosin a is still in question.

Prothymosin a is

a 112 aa highly acidic phosphoprotein (Haritos et al., 1984; Barcia et al., 1992;
Sburlati et al., 1993; Trumbore et al., 1997) that was believed to be a precursor
of thymosin a, a potential thymic hormone. However, this is no longer the
present held view (Haritos et al., 1984; Manrow et al., 1991; Sburlati etal.,
1991) since thymosin a may be a degradation artifact of prothymosin a
(Hannappel et al., 1982; Haritos et al., 1984) and prothymosin a has been
detected in multiple tissues outside the thymus (Haritos et al., 1984). Currently
prothymosin a is believed to be involved in cell proliferation (Sburlati et al.,
1991). Evidence supporting this hypothesis is seen in multiple ways. Mitogen
activated T cells show an increase in prothymosin a mRNA (Eschenfeldt &
Berger, 1986) and antisense oligomers against prothymosin a mRNA have
been found to inhibit cell division (Sburlati et al., 1991). Interestingly,
overexpression of human prothymosin cx in yeast results in inhibition of cell
division. This inhibition was found to be partially dependent on the nuclear
localization of the protein, since mutation of an NLS within prothymosin a
relieved the blockade on cell division (Pavlov et al., 1995; Rubtsov et al., 1997).
However, a second mutant that suppresses cell division inhibition does not
affect prothymosin a’s nuclear import (Rubtsov et al., 1997), and thereby
affects the function of prothymosin a in a novel way.
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Prothymosin a has been detected in both the nuclear and cytoplasmic
compartments. Microinjection of prothymosin a into the cytoplasm oi Xenopus
oocytes leads to its nuclear import (Watts et al., 1989) and p-galactosidaseprothymosin a (Manrow et al., 1991) as well as GFP-prothymosin a fusion
proteins (Rubtsov et al., 1997) were found to be localized predominantly in the
nucleus. Mutations of these fusion proteins lead to the discovery of a bipartite
NLS within prothymosin cx (Manrow et al., 1991; Rubtsov etal., 1997). However,
Makarova et al. (1989) identified cytoplasmic prothymosin a covalently linked to
RNA in mouse, bovine, yeast and human cells. They believe that prothymosin
a is preferentially found in the cytoplasm when bound to RNA. Interestingly,
Vartapetian et al. (1992) discovered regions within the E. Coli genome that are
homologous to the coding region of the human prothymosin a gene.
Subsequent experiments (Vartapetian et al., 1997) showed that when rat
prothymosin a was overexpressed in E. Coli it was found to be linked to diverse
tRNA molecules at their 5’end. Since the tRNA binding region was localized to
the NLS of prothymosin a, these authors speculate that prothymosin <x’s
interaction with tRNA may affect its subcellular location.
Manrow et al. (1991) suspected that prothymosin a might serve as a
nuclear shuttle/carrier protein. Several lines of evidence support prothymosin cx
possibly having a role in transport. First, prothymosin a is localized in the
nucleus and bears a bipartite NLS (Manrow et al., 1991; Rubtsov et al., 1997).
Second, prothymosin a interacts with the NES of Rev (Kubota et al., 1995).
Third prothymosin cx is found bound to RNA in the cytoplasm (Makarova et al.,
1989). Therefore a new hypothesis for prothymosin ex’s function may include
facilitating the export of cellular RNAs. The exact role that prothymosin cx plays
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in Rev function still needs further study, but Kubota et al. (1995) speculates it
may be involved in Rev/RRE export.
F. The Rev Binding Element

Rev interacts with the RRE in vitro and in vivo (Zapp & Green, 1989;
Daefler et al., 1990; Bohnlein et al., 1991; Huang et al., 1991; Malim & Cullen,
1991; Daly etal., 1993a; Battiste et al., 1994; Jensen etal., 1995; Charpentier et
al., 1997). This interaction has been found to be essential for Rev function and
HIV-1 replication (Feinberg et al., 1986; Sodroski et al., 1986; Rosen et al.,
1988; Dayton et al., 1989; Olsen et al., 1989; Huang et al., 1991; Malim &
Cullen, 1993). A primary high affinity binding site, called the Rev Binding
Element (RBE) (Bartel et al., 1991), has been identified within the multiple
stem-loops of the RRE (Bartel et al., 1991; Cook et al., 1991; Heaphy et al.,
1991; Kjemsetal., 1992; Tiley etal., 1992) (Fig. 2). The RBE is located in
regions within and adjacent to stem-loop 2B, and it has been determined that it
forms a stem-purine rich asymmetric bulge-stem structure (Bartel et al., 1991;
Heaphy et al., 1991; Kjems et al., 1992). RBE deletion or substitution mutants
inhibit Rev-RRE interaction in vitro and cause RRE containing mRNAs to
become unresponsive to Rev in vivo (Holland et al., 1990; Malim et al., 1990;
Olsen et al., 1990b; Huang et al., 1991).
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1. Rev basic domain peptides interact specifically with the RBE

Short RNA molecules that contain the RBE motif have been shown to
interact with Rev protein or a 17 aa Rev basic domain peptide (Rev34-50-am
peptide; 34-TRQARRNRRRRWRERQR-AMIDE-50) in a specific manner
(Kjems et al., 1992). Rev protein and Rev34_50-am peptide both: inhibit the
splicing of RRE containing RNAs in vitro (Kjems et al., 1991; Kjems & Sharp,
1992), interact at basically identical sites on the RRE (Kjems et al., 1991;
Kjems et al., 1992) and contain a significant amount of alpha helical content
(Daly et al., 1990; Tan et al., 1993; Auer et al., 1994; Tan & Frankel, 1995).
Modifications of the peptide that increase its alpha helical content result in a
parallel increase in specific interaction with the RBE (Tan et al., 1993; Tan &
Frankel, 1994). The N-terminal half of the Rev protein, including its basic
domain, appears to be largely structured with alpha helixes, and has been
proposed to form a helix-loop-helix motif (Auer et al., 1994). These results
suggest that the Rev34_50-am peptide is capable of adopting a conformation
similar to the basic RNA binding/nuclear localization domain of the wild type
Rev protein.

2. RBE aptamers

Utilizing systematic evolution of ligands by exponential enrichment
(SELEX) (Ellington & Szostak, 1990; Tuerk & Gold, 1990; for review see Burke &
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Berzal-Herranz, 1993), aptamers were selected from random sequence pools
based on the RBE (Giver et al., 1993a; Giver et al., 1993b; Tuerk & MacDougalWaugh, 1993) (Fig. 3). Three classes of aptamers emerged that were able to
interact with higher affinity to Rev (Fig. 4). First, based on Giver’s nomenclature
a class of aptamers was found that contained a RBE-like motif (class III),
differing only by five nucleotide substitutions. Second, a group of aptamers
showed a novel Rev binding motif containing one or two bulged nucleotides
(class II). The last class of aptamers selected demonstrated the highest
affinity to Rev and contained a combination of the first two motifs (class I).
Interestingly, these in vitro selected RBE aptamers are able to functionally
replace the RBE within the RRE in vivo (Symensma et al., 1996). Class I and
class III RBE aptamers were substituted for the wild type RBE sequences of
stem-loop 2B. They were found to work as well as the wild type RBE when Rev
levels were saturating, and between two and six times better than the wild type
sequences, when Rev levels were limiting in vivo (Symensma et al., 1996).

3. Anti-Rev therapeutic strategies

Multiple anti-Rev therapeutic strategies have been developed.
Expression of exogenous RRE/RBE decoys (which “sponge up” Rev protein)
(Bevec et al., 1994; Bahner et al., 1996; Bauer et al., 1997; Inouye et al., 1997)
and anti-rev (Michienzi et al., 1996)/anti tat-rev ribozymes (Zhou et al., 1994;
Zhou et al., 1996) (which inhibit Rev protein production) or composite decoy-
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Figure 3. Systematic Evolution of Ligands by Exponential Enrichment (SELEX).
T7 polymerase oligo templates are synthesized with a randomized RBE
sequence. In vitro transcription allows for the production of variable RNAs from
these templates, some of which will be selected by their ability to interact with
Rev. Selected RNAs are eluted and reverse transcribed allowing for the
production of cDNA. PCR is then used to make a double stranded product
from the cDNA, followed by additional rounds of PCR to amplify the double
stranded product. In vitro transcription of these templates now produces RNAs
that are able to interact with Rev on a whole with higher affinity than the original
transcribed RNA pool. Repeated rounds of this cycle allows for the isolation of
populations of RNA that interact with Rev with high affinity, these ligands are
designated RBE aptamers (adapted from Tuerk & MacDougal-Waugh, 1993).
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ribozyme molecules (Yamada et al., 1996) are a few approaches that have
been found to block Rev function and/or inhibit HIV-1 replication in vivo. Since
RBE aptamers interact more tightly with Rev compared to the wild type RBE
(Giver et al., 1993a; Giver et al., 1993b; Tuerk & MacDougal-Waugh, 1993;
Symensma et al., 1996), they may therefore prove to be more effective Rev
decoys. This may be true for the aptamer alone and/or the aptamer in chimeric
ribozyme form.

G. Summary

Rev is 116 amino acids in length and binds as a multimer to a 234
nucleotide long Rev Response Element located in the envelope region of HIV-1
mRNA. Early in the HIV-1 replication cycle, when Rev levels are low, HIV-1
transcripts reach the cytoplasm exclusively in the form of several different
multiply spliced, 2 kb mRNA species that encode the HIV-1 regulatory proteins,
Tat, Rev and Nef (Fig. 5A). Once a critical level of Rev expression has been
achieved, expression of the 9 kb (unspliced) and 4 kb (singly-spliced) viral
mRNA’s that encode the viral structural genes are activated, possibly by Rev
mediated inhibition of splicesome assembly and/or Rev increasing access of
these mRNA species to the eukaryotic export machinery. Rev thereby allows
for expression of the gag and pol genes (9 kb mRNA class) and the env, vif
vpu, vpr and tat genes (4 kb mRNA class). Consequently, Rev can be thought
of as a switch that modulates the transition from early to late gene expression.
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Figure 5. The Domain Structure and Cellular Role of Rev. A) Rev plays an
essential role in the HIV-1 life cycle. It binds to the RRE located in 9 kb and
4 kb viral mRNA transcripts, and selectively increases their transport to the
cytoplasm. Rev mediated mRNA export allows for the expression of viral
structural and accessory proteins as well as active virion formation. B) Rev has
multiple functional domains. Its nuclear localization sequence (NLS)/arginine
rich motif (ARM) is involved in importing Rev to the nucleus and RRE binding.
Rev interacts with the RRE as a multimer. The regions implicated in
multimerization are shown. Rev then activates mRNA export using it’s leucine
rich nuclear export signal (NES). Adapted from Cullen and Malim (1991).
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The Rev protein has contains multiple functional domains (Fig. 5B). The
first region is a basic, arginine rich motif, that mediates RRE binding and
nuclear localization. This region is essential for Rev’s function in vivo and for
RNA binding in vitro. The second region is located in the immediate vicinity of
the amino terminal and carboxyl terminal flanking sequences of the basic
domain, and is involved with in vitro multimerization. The third region, an
activation domain, is a small leucine rich motif, involved in multimerization in
vivo but not in vitro, is essential for Rev’s function and has now been defined
as a nuclear export signal.
Numerous studies have shown that Rev shuttles between the nucleus
and the cytoplasm. Using its nuclear localization/RNA binding domain Rev
enters the nucleus and binds to RRE containing transcripts. The primary
binding site in the RRE is stem-loop 2B, where structure as well as a
non-canonical base pair are important for recognition. It has also been shown
that Rev is dependent upon its nuclear export sequence to translocate to the
cytoplasm with the RRE-containing viral transcript via SSrRNA, snRNA and
mRNA export pathways. Mutants in Rev’s nuclear export sequence can enter
the nucleus but are unable to shuttle out, thereby failing to mediate the nuclear
export of RRE-containing viral transcripts. The interpretation of these
experiments is that nuclear export sequence mutants are unable to bind the
cellular factor(s) required for their export and consequently are not able to
mediate nuclear export of RRE-containing transcripts.
As described in this introduction retroviruses have indeed found ways to
adapt to the human host that are fairly complex. As we learn about the
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pathways of HIV’s replication cycle in an attempt to discover how to inactivate
the virus, we will also learn more about normal eukaryotic cell function. Rev
has become an attractive target for HIV therapy because of its essential role in
viral production, and as a byproduct we have gained a tremendous wealth of
knowledge about RNA export. Numerous questions, however, remain
unanswered and there still is no cure for AIDS. Only God in his omnipotence
knows what will happen in the future.

H. Research objectives
Many authors have proposed that cellular factors are important in
facilitating Rev function (Malim et al., 1989b; Olsen et al., 1990a; Venkatesh &
Chinnadurai, 1990; Malim & Cullen, 1991; Malim et al., 1991; McDonald et al.,
1992; Bogerd & Greene, 1993; Madore et al., 1994). Several candidate factors
exist (Fankhauser et al., 1991; Ruhl et al., 1993; Luo etal., 1994; Kubota et al.,
1995), but at the time our research was initiated none of the factors identified
appeared to play a central role in Rev protein transport. In order to identify Rev
interacting cellular proteins, we utilized the yeast two-hybrid system (Fields &
Song, 1989; Chien et al., 1991) to screen a yeast genomic library for Rev
binding factors potentially important for Rev-mediated transport. We chose this
system because once a gene of interest was identified as coding for proteins
that bound to Rev, the plasmid containing the gene was readily accessible for
sequence identification and further domain studies.
Yeast was chosen as a model system because of three reasons. First it
was shown that Rev was able to function in yeast as it does in mammalian
cells. Stutz and Rosbash (1994), showed that Rev enhances yeast pre-mRNA
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nucleocytoplasmic translocation in an RRE-dependant manner. Rev’s ability to
affect pre-mRNA localization was monitored indirectly, by examining the
expression of a RRE-containing CUP1 reporter gene construct. In the
presence of Rev the reporter mRNA is transported from the nucleus to the
cytoplasm allowing expression of the CUP1 protein, a copper chelator, which
when synthesized in yeast enables growth on copper containing medium in a
dose-dependent manner. Knowing that Rev functions in yeast as it does in
mammals, we hypothesized that Rev-yeast interacting factors found should
have mammalian homologues. Second, it’s simpler to screen the complete
genome of yeast because of its smaller size compared with mammalian
genomes. Third, yeast are easier to manipulate genetically.
Our goals included using the yeast two-hybrid system to characterize
Rev’s interaction with any identified binding protein(s). Rev has multiple
functional domains. We wished to determine whether Rev’s nuclear import or
export domains were responsible for any interactions found. Newly identified
proteins may also possess specific domains or regions that could mediate
protein-protein interaction. We, therefore, planned to determine which regions
of the factor(s) identified interact with Rev. Last we wished to determine
whether Rev’s interaction with the identified factor(s) was direct or indirect. To
accomplish this last goal purification of the identified protein(s) and the use of
in vitro binding assays to determine direct interaction would be used.
Potential interacting factors included novel or previously identified
proteins involved in splicing, transport, translation or localization. We
suspected that proteins identified would be important somewhere along the
Rev import and/or export pathway. The above speculations allowed for the
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protein to be potentially located within the nucleolus, nuclear speckles,
nucleus, nuclear pore, cytoplasm, or ribosomes. On the other hand, the
potential factor could be involved in trafficking between some or all of the above
mentioned compartments. Identification of factors that facilitate Rev function
will not only aid our understanding of the HIV-1 life cycle, but will also enable a
better understanding of protein and RNA transport within normal eukaryotic
cells.
In addition, studies on HIV-1 Rev RNA-protein interactions are included
in this dissertation. These experiments address: 1) specific interactions of
Rev protein or Rev peptides with in vitro selected Rev binding aptamers, and
2) the use of novel DMA templates for in vitro transcription of RBE aptamers.
These studies were initiated after unsuccessful attempts to show Rev/RRE
complexes interact directly with identified Rev binding proteins in vitro.

Rev RNA-Protein interaction studies were divided into three parts:

a. Ascertaining whether a chimeric class I RBE aptamer-ribozyme
molecule affects the ability of the aptamer to interact with Rev

RRE/stem-loop 2-ribozyme containing molecules have been shown to
inhibit HIV-1 in vivo ( Yamada et al., 1996). These molecules were found to
function both as an RNA decoy and ribozyme. In addition, ribozyme function in
the chimera RNAs was found to be enhanced over wild type anti-HIV ribozymes.
These authors speculated that this was due to one of three possibilities:
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1) binding of Rev to stem-loop 2 allowed for transport of the ribozyme to areas
where it colocalized with its target within RRE-containing mRNAs. 2) Rev’s
interaction with the chimeric RNA increased the ribozyme’s intrinsic activity.
3) The additional RNA nucleotides stabilized the ribozyme within the cell. Three
members of the Rossi laboratory, including myself, have decided to address
different aspects of the first two possibilities utilizing a novel class I RBE
aptamer-ribozyme (Kanopka et al., 1998) (Fig. 6). RBE aptamers are known to
interact with higher affinity to Rev than the wild type stem-loop 2 of the RRE
(Giver et al., 1993a; Giver etal., 1993b; Tuerk & MacDougal-Waugh, 1993;
Symensma et al., 1996). Therefore the decoy region of the dual molecule may
prove to be more potent than the wild type inhibitory sequence.
My goal in this project was to assess Rev’s ability to interact specifically
with the RBE aptamer-ribozyme. Although Yamada et al. (1996) proposed that
this interaction took place, it was not shown in vitro. This specific interaction
would be necessary for Rev to be able to selectively transport the chimeric
molecule to regions that contain RRE-bearing mRNAs to which the ribozymes
are targeted. To accomplish this goal Rev RBE aptamer-ribozyme mobility shift
assays were performed in the presence or absence of specific or nonspecific
competitor RNAs.
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b. Determining the specificity of a modified Rev basic domain peptide
to class I and class III RBE aptamers

Modifications of the 17 aa Rev34_5o-am peptide have been shown to
increase its alpha helical content, thereby facilitating its ability to interact
specifically with the RBE (Tan et al., 1993). Addition of a succinyl group to the
amino-terminal aa of the peptide, and the sequence Ala-Ala-Ala-Ala-Arg-amide
to the carboxyl-terminal aa of the peptide, resulted in an increase of alpha
helical content from 4% in Rev34_50-am to 51% in suc-Rev34-50-AAAAR-am
(Tan et al., 1993). The overall goal of our collaborator Dr. Yuan Chen is to work
on solving the solution structure of class I and class III aptamers bound to the
latter mentioned modified peptide using nuclear magnetic resonance. The
information gained will be helpful in designing new RNA molecules that may
be able to interact more strongly with Rev and therefore potentially may function
as more effective anti-Rev therapeutic agents.
My goal was to show by in vitro methods that the class I and class III
RBE aptamers indeed are able to form specific complexes with the
suc-Rev34_50-AAAAR-am peptide. RBE aptamer competition mobility shift
assays utilizing modified Rev peptides has not been published in the literature.
Therefore we chose to use this method to address the specificity of the
interaction.
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c. The use of novel DNA templates for in vitro transcription of Rev
binding aptamers

Screening for RNA molecules that can perform a specific task can be a
multiple step procedure. For example the testing of theoretical RNA elements
which interact with a protein in vitro and in vivo may involve ordering oligos to
create a construct that can be used for in vitro transcription. These oligos
would also have to be designed in such a way that they could be cloned into a
vector for further in vivo testing. This is necessary because injection of DNA
oligos into cells leads to their early demise by degradation.
To overcome some of these labor intensive steps we are in the process
of developing a novel approach to in vitro and in vivo transcription by T7
polymerase. In this method a single DNA molecule folds on itself to create the
double stranded T7 promoter site and a looped out single stranded region
contains the coding sequence for an RNA molecule of interest (Fig. 7).
Following the coding sequence is a unique T7 polymerase termination motif of
10 propane diol units. 5’-5’ linkage of two of these templates forms a
bidirectional transcriptional template, with the two units separated by spacer
residues adjacent to the T7 promoter sequence. The 3’ ends of the molecule
are modified by thiol residues in order to inhibit//? vivo degradation.
Preliminary results by in our laboratory have shown that the 5’-5’ linked
template is able to transcribe twice as much RNA as an equimolar amount of
single template. Our overall goal is to test these molecules for transcriptional
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function both in vitro and in vivo. Towards these goals we sought to test
whether a single template could be used to transcribe a class I Rev binding
aptamer. Which will then be subsequently tested for specific Rev binding
capability by mobility shift assays.

CHAPTER 2

MATERIALS AND METHODS

A. Materials

1. S. cerevisiae and E. coli strains

CTY10-5d {MATa ade2 trp1-901 leu2-3, 112 his3-200 gal4 ga!80
URA3::lexA op-lacZ) was kindly provided by Dr. Glen Manthey (Beckman
Research Institute of the City of Hope, Duarte, CA). It was used in the initial Rev
two-hybrid screen and subsequent Rev-nucleoporin two-hybrid domain
analysis. HF7c {MATa, ura3-52, his3-200 lys2-801, ade2-101, trp1-901 leu2-3,
112, gal4-542, gal80-538, LYS2::GAL1-HIS3, URA3::(GAL4 17-mers)3-CYC1lacZ) was kindly provided by Dr. Dong Ho Kim (Beckman Research Institute of
the City of Hope, Duarte, CA), and was utilized in the reverse two-hybrid screen.
E. coli MC1061 (F- araD139 k(ara-leu) 7696 galE15 galK16 A(lac) X74
rpsL (Strr) hsdR2 (rk" mk+) mcrA mcrB1) and XL1-Blue (F' ::Tn70 proA+B+
laclQ A(lacZ)M15/recA1 endA1 gyrA96 (Nalr) thi hsdR17 (rk- mk+) supE44
relA1 lac~) were used for propagation of plasmid DNA and yeast shuttle
vectors. E. co//SURE 2 (e14-(McrA~) A{mcrCB-hsdSMR-mrr)171 endA1
supE44 thi-1 gyrA96 relA1 lac recB reed sbcC umuC::Tn5 (Kanr) uvrC [F proAB
lacIQZ AM15 Tn10 (Tetr) Amy Camr] ) supercompetent cells were purchased
from Stratagene (La Jolla, CA) and were used for propagation of the yeast
genomic library screened in the reverse two-hybrid assay.
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2. Growth Media
Yeast strains were grown in YPD (10 g/L yeast extract, 20 g/L peptone,
20 g/L dextrose) or CSM drop-out media which contains: 0.8-1.3g/L drop out
supplements (purchased from BIO 101 Inc., La Jolla, CA), 1.7 g/L yeast
nitrogen base-AA/AS, 5 g/L ammonium sulfate, 20 g/L dextrose, 1 pellet of
sodium hydroxide. E. coli strains were grown in LB (10 g/L tryptone, 5 g/L yeast
extract, 1 pellet sodium hydroxide, 1 g/L dextrose), or SOC media (20 g/L
tryptone, 5g/L yeast extract, 0.5 g/L sodium chloride, 5 g/L MgS04.7H20,
20 mM dextrose). For plates addition of 20 g/L agar was added to the
appropriate media.

3. Chemicals

Unlabeled deoxynucleotides were obtained from Boehringer Mannheim
(Indianapolis, IN). [a-32p] \jjp and [y-^R] ATP were obtained from
Amersham Life Science Inc. (Arlington Heights, IL) and ICN Pharmaceuticals
Inc. (Costa Mesa, CA). tRNA was obtained from Boehringer Mannheim
(Indianapolis, IN). All other chemicals were obtained from Fisher Scientific Co.
(Irvine, CA) or Sigma Chemical Co. (St. Louis, MO).

4. Enzymes

DNase I was obtained from Ambion Inc. (Austin, TX) and Boehringer
Mannheim (Indianapolis, IN). RNase inhibitor was obtained from Promega
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Corp. (Madison, Wl). T4 polynucleotide kinase and T7 RNA polymerase were
obtained from New England Biolabs Inc. (Beverly, MA). T4 DNA ligase and
Klenow (DNA polymerase I, large fragment) were obtained from Boehringer
Mannheim (Indianapolis, IN). Restriction enzymes were obtained from New
England Biolabs (Beverly, MA), Boehringer Mannheim (Indianapolis, IN) and
Promega Corp. (Madison, Wl).

5. Proteins

HIV-1 Rev wild type and transdominant (deletion of Leu 78 and Glu 79)
proteins were obtained through the AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH: from Dr. David Rekosh, Dr. MarieLouise Hammarskjbld and Dr. Michael Orsini.

B. Methods

1. p-galactosidase colony filter assay
[3-galactosidase yeast colony filter assay was adapted from Breeden
and Nasmyth (1985). Supported nitrocellulose transfer and immobilization
membranes (purchased from Schleicher & Schuell, Keene, NH) were laid onto
yeast containing plates and allowed to wet completely. The filters were then
lifted from the plates with forceps and immersed in liquid nitrogen for 20 to
60 seconds to allow for the yeast cells to be permeabilized. Using forceps the
filters were then removed from the liquid nitrogen and thawed, colony side up,
for a few minutes at 25 °C. The filters were then placed, colony side up on
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Whatman 3MM chromatography paper, which had been presoaked in 1 mg/ml
X-Gal in Z-buffer, within a covered polystyrene petri dish. Z-buffer contains:
60 mM Na2HP04, 40 mM NaH2P04, 10 mM KCI, 1 mM MgSCM, 40 mM 2mercaptoethanol. To decrease precipitation X-Gal initially is dissolved in N,Ndimethylformamide at 100 mg/ml, then diluted 100 fold in Z-buffer prewarmed
to 37 °C. The filters were then incubated from 1 to 24 hrs at 37 °C, and
evaluated periodically for the presence or absence of color change.

2. Yeast two-hybrid screen
pBTM116 LexA/Rev1A, contains an in frame fusion between the
complete LexA protein and HIV-1 Rev optimized for yeast expression. This
plasmid was derived by digestion of pBS-Rev1A (received from Dr. David
Elkins) with EcoRI and BamHI, the resulting insert was ligated into EcoRI and
BamHI of pBTM116 (obtained from Dr. Glen Manthey, Beckman Research
Institute of the City of Hope, Duarte, CA). pBTM116 LexA/Rev1 A was
transformed (using an alkali-cation yeast transformation kit, BIO 101, La Jolla,
CA) into the yeast strain CTY10-5d, which contains four integrated binding sites
for LexA dimers inserted upstream of the transcriptional start site of a GAL1lacZ reporter gene. For the library screen, three GAL4/AD yeast genomic
libraries within plasmids pGAD1, 2, and 3 (obtained from Dr. Stan Fields,
University of Washington, Seattle, WA) were separately transformed into the
pBTM116 LexA/Rev1A containing CTY10-5d yeast. 200,000 transformants
were selected on -Trp-Leu CSM drop-out media, and subsequently tested for
reporter gene activation by the p-galactosidase colony filter assay.
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Plasmids from yeast colonies that activated reporter gene transcription
were then isolated by a procedure described by Hoffman (1993). Yeast library
plasmids were then separated from the LexA/Rev1A plasmids by
transformation into bacteria, plasmid isolation and diagnostic restriction
digests. Library clones were checked for LexA/Rev independent ability to
activate transcription (false positive) by transforming back into: CTY10-5d +
pBTM116 (Rev absent, negative control), CTY10-5d + pBTM116 LexAA/pr
(negative control) and CTY10-5D + pBTM116 LexA/Rev1A (positive control),
then tested with the (3-galactosidase colony filter assay. Transformants that
could activate transcription only in the presence of Rev were designated true
positives. Sequencing of the GAL4/AD-library fusion joint from true positives,
was followed by a computer based search of GenBank using BlastN homology
searching to identify the Rev interacting yeast factors.

3. Yeast two-hybrid domain analysis of Rev-nucleoporin interaction

pGAD424 NUP100 constructs were derived from the yeast library vector
VY53 which was obtained in the Rev two-hybrid screen. In frame fusions were
made between the GAL4/AD of pGAD424 (Clonetech, Laboratories Inc., Palo
Alto, CA) and NUP100 aa: 19-583, 611-959, 121-583, 19-121, 121-277, 277531, 277-328, 350-531, 328-350, 402-583, 121-383.
pRS425 NUP49 was derived from the yeast pGAD library vector VY63,
which was also obtained in the Rev two-hybrid screen. VY63 was digested with
Sea I and Hind III, generating a 2.3 Kb fragment which was cloned into the Sma
I and Hind III sites of pRS425 (Christianson et al., 1992). pGAD424 NUP49
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constructs were derived by performing PCR on pRS425 NUP49, the resulting
insert was digested with Sal I and partially digested with Pst I. Fragments
bearing sequences coding for: aa 5-431,5-243 and 5-155 of NUP49 were then
ligated to Sal l-Pst I digested pGAD424, giving rise to in frame fusions between
5’ regions of NUP49 and the GAL4/AD of pGAD424.
p49AD203 constructs were created by Dr. Lisa Scherer (Beckman
Research Institute of the City of Hope, Duarte, CA). Briefly the GAL4/AD of
pGAD424 was deleted and replaced by insertion of DNA coding for the
3’ NUP49 acidic domain from aa 258-472 (obtained by PCR from pRS425
NUP49), giving rise to p49AD203. DNA coding for aa 19-583 of NUP100 and
aa 5-290 of NUP49 were then cloned in frame to the NUP49 acidic domain of
the p49AD203 vector to give rise to p49AD203(240-4) and p49AD203(241-1).
pBTM116 Rev1A (wildtype), RevMIO, Rev4C (truncated Rev) and Vpr
constructs were created by Dr. Lisa Scherer (Beckman Research Institute of
the City of Hope, Duarte, CA). All constructs contain in-frame fusions between
the LexA protein and the HIV wild type or mutant proteins. Mutants RevMIO and
Rev4C contain substitutions (LE-*DL; aa 78,79), and a deletion of aa 1-52,
respectively.
In order to define regions of nucleoporins interacting with the Rev
protein, CTY10-5d yeast containing pBTM116 LexA/Rev1 A were transformed
(using an alkali-cation yeast transformation kit, BIO 101, La Jolla, CA) with:
pGAD424 NUP100 constructs, pRS425 NUP49, pGAD424 NUP49 constructs
and p49AD203 NUP100 and NUP49 hybrid nucleoporin constructs separately.
To delineate the regions of Rev that interacted with the nucleoporins, CTY10-5d
yeast containing pBTM116 LexA/Rev1A, pBTM116 LexA/Rev4C or pBTM116
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LexA/RevM10 were transformed with: pGAD424 NUP100(19-583) or pRS425
NUP49. Transformants were selected on -Trp-Leu CSM drop-out media and
subsequently tested for reporter gene activation by the p-galactosidase colony
filter assay.

4. Nucleoporin expression and purification

pQE30(101-2) was derived from the Rev interacting yeast two-hybrid
library clone VY53, that contains aa 19-959 of NUP100. A DNA insert coding for
aa 19-593 of NUP100 was obtained by PCR from VY53, the resulting fragment
was digested with Sal I. pQE30(105-1) was derived from pRS425 NUP49, that
contains the entire 472 aa of the NUP49 gene. NUP49 insert DNA was
obtained by PCR, and was digested with Sal I and Hind III. NUP100 5’ and
NUP49 inserts were then ligated into the Sal I and Sal l-Hind III sites of the sixHis tag pQE30 vector (QIAGEN Inc., Chatsworth, CA).
pQE30(105-1) or pQE30(101-2) expression plasmids, coding for six-His
tagged: NUP49 and the amino terminus of NUP100, respectively, were both
expressed in an identical manner using the QIAexpressionist system from
QIAGEN Inc. (Chatsworth, CA).

Large scale expression cultures were obtained

by inoculating 20 ml of LB-broth (containing 100 (.ig/ml ampicillin and 25 ^g/ml
kanamycin) with a single M15 [pREP4] colony, previously transformed with the
appropriate expression plasmid. The bacteria were grown at 37 °C overnight,
with vigorous shaking. Then 500 ml LB-broth (containing 100 (.ig/ml ampicillin,
25 f.ig/ml kanamycin) was inoculated at a 1:50 dilution with the uninduced
overnight culture. The bacteria were then incubated at 37 °C with vigorous
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shaking until an O.D. at A0OO reached 0.8 . Next, the culture was induced by
the addition of Isopropyl Beta-D-Thiogalactopyranoside to a final concentration
of 2 mM, and returned to shaking incubation at 37 °C for 5 hours. The cells
were harvested by centrifugation at 4000xg (6500 rpm, Sorvall GS-3) for
10 minutes at 4 °C. Then the bacterial pellet was stored at -70 °C.
Denaturing purification of the nucleoporins was carried out according to
the QIAexpressionist protocol. The cells were thawed for 10 min and
resuspend in 12 ml lysis Buffer A, pH 8 (6 M Guanidine Hydrochloride, 0.1 M
Sodium phosphate, 0.01 M Tris/Hydrochloride). The cells were then stirred for
1 hr at 25 °C and the lysate was subsequently centrifuged at 10,000xg
(12,000 rpm, Sorvall SA-600) for 15 min at 4 °C. The supernatant was loaded
at a flow rate of 10-15 ml/hr, onto a 4 ml nickel-nitrilo-tri-acetic acid column pre
washed with 5 column volumes (approx. 50 ml) water and pre-equilibrated with
10 column volumes (approx. 100 ml) lysis buffer A.

The column was then

washed at 25 °C with: 15 column volumes (approx. 150 ml) lysis Buffer A and
then 15 column volumes (approx. 150 ml) modified lysis Buffer A, pH 6.3 (6 M
Guanidine Hydrochloride, 0.1 M Sodium phosphate, 0.01 M Tris/Hydrochloride).
Solid-phase renaturation of purified proteins was performed according
to a procedure described by Petty (1993) with some modifications. The column
was washed at 4 °C at a flow rate of 25 ml/hr with: 25 ml of 1:1 (v/v) MCAC-20
pH 7.9 (20 mM Tris/Hydrochloride, 500 mM Sodium Chloride, 20 mM Imidazole,
0.5 mM Phenylmethylsulfonyl fluoride) /GuMCAC-20 pH 7.9 Buffer (6 M
Guanidine Hydrochloride, 20 mM Tris/Hydrochloride, 500 mM Sodium Chloride,
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20 mM Imidazole, 0.5 mM Phenylmethylsulfonyl fluoride), 25 ml of 3:1 (v/v)
MCAC-20/GuMCAC-20 Buffer, 25 ml of 7:1 (v/v) MCAC-20/GuMCAC-20 Buffer,
4 ml of 16:1 (v/v) MCAC-20/GuMCAC-20 Buffer, 4 ml of 32:1 (v/v) MCAC20/GuMCAC-20 Buffer, 4 ml of 64:1 (v/v) MCAC-20/GuMCAC-20 Buffer, 25 ml of
MCAC-20 Buffer. The proteins were then eluted with 40 ml elution Buffer
(4 ml elution fractions), pH 7.4 (800 mM Sodium Chloride, 30 % Glycerol,
50 mM Tris/Hydrochloride, 0.5 mM Phenylmethylsulfonyl fluoride, 250 mM
Imidazole), quantified using a Bio-Rad Microassay procedure (using a protein
assay kit purchased from Bio-Rad Life Science Group, Richmond, CA) and
stored at -70 °C.
5. Rev-nucleoporin mobility supershift assay
pTZU6+27RBE-mutant (mt) envribozyme (Konopka et al., 1998) (RBE =
Rev Binding aptamer 6a; Tuerk & MacDougal-Waugh, 1993; Jensen et al.,
1994) was obtained from Dr. David Engelke (University of Michigan Medical
School, Ann Arbor, Ml). This plasmid was linearized with Xba I, allowing for the
transcription of the 54 nucleotides of the RBE aptamer 6a alone from the T7
promoter. Labeled RBE aptamer 6a was transcribed using 1 fig of linearized
template in a T7 Maxiscript reaction (using a Maxiscript kit purchased from
Ambion Inc., Austin, TX), modified by addition of [cx-32p] UTP (25 (.iCi,
3000 Ci/mmol) and 62 f.iM total cold UTP. The transcription was performed at
37 °C for 1 hr, and the template was removed by addition of 2 units DNase I
with subsequent incubation at 37 °C for 15 min. The sample was then
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extracted with phenol-chloroform and chloroform, then ethanol precipitated and
resuspended in TE. Radioactive counts per minute (cpm) were determined by
Cerenkov counting.
The RNA-protein supershift assay was performed at room temperature
using a protocol described by Daly et al. (1993a) with some modifications. The
binding reaction volume was 10 \.i\ and each sample contained: 10 units
RNase inhibitor, 10 mM K2HPO4, 10 mM NaH2P04, 140 mM KCI and 10 jig
tRNA. Rev protein was allowed to bind with the radiolabeled RNA (previously
heated at 85 °C for 4 min and cooled on ice for 5 min) for 15 min at 25 °C.
NUP49 was then added to the samples and allowed to bind for an additional
45 min. 2 fxl of loading buffer containing (0.25% bromophenol blue, 0.25%
xylene cyanol FF and 30% glycerol in water was added to the samples, which
were loaded onto a 5% TBE nondenaturing polyacrylamide gel (23 cm x 23 cm
x 0.2 mm). The gel was electrophoresed for 15 mA for 5 min, 1 hr and 30 min
at 5 mA, and approximately 1 hr at 10 mA, with subsequent drying and
exposure for autoradiography.

6. Rev-nucleoporin ligand blot assay

pTZRRE was derived from pTZU6+27RRE (obtained from Dr. David
Engelke, University of Michigan Medical School, Ann Arbor, Ml) by the procedure
used to derive pTZCCmt from pTZU6+27CCmutant (mt) described in section
2.B.9. A 252 nt radiolabeled RRE was transcribed by Dr. Lisa Scherer
(Beckman Research Institute of the City of Hope, Duarte, CA). RNA was
quantified with use of a spectrophotometer.
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Nucleoporins were bound at 25 °C to supported nitrocellulose (MSI
micron separations Inc., Westborough, MA) using a Bio-Dot microfiltration
apparatus (Bio-Rad Laboratories, Hercules, CA) according to the
manufacturers protocol. Binding was performed in 100 f.il Tris-buffered saline
(TBS; 20 mM Tris pH 7.6, 137 mM NaCI) for 30 min. The samples were then
washed two times with 400 (.il TBS-Tween (TBS-T; 20 mM Tris pH 7.6, 150 mM
NaCI, 0.05% Tween-20) and the membrane was subsequently removed from
the apparatus and blocked for 1 hr with 3% BSA in TBS. The membrane was
then washed two times for 10 min, first with TBS-T and then with TBS.
Radiolabeled RRE pre-incubated at 25 °C for 30 min, with or without Rev or
transdominant Rev, in binding buffer [60 mM NaCI, 12 mM Hepes pH 7.9,
12 mM DTT, 4 mM Tris pH 7.8, 4 mM MgCl2, 30 units RNase inhibitor; modified
from Daefler et al. (1990)] was then added to the membrane and further
binding was allowed to proceed at 4 °C for 15 min. The membrane was
washed with TBS at 25 °C, covered with saran wrap and exposed for
autoradiography.

7. GAL4/BD yeast library amplification

A GAL4/BD yeast genomic library within the plasmid pGBT-CYH
(obtained from Dr. Stan Fields, University of Washington, Seattle, WA) was
used for the reverse two-hybrid screen. The library was amplified by
transformation into E. coli Sure2 supercompetent cells (according to the
manufacturers procedure, Stratagene, La Jolla, CA). 20,000 - 50,000 colonies
per 150 mm LB Amp plate were scraped off to give approximately =2.4 x 10^
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pooled colonies. Library plasmid isolation was obtained using a QIAGEN
Mega kit (QIAGEN Inc., Chatsworth CA) according to the manufacturer’s
protocol.

8. Reverse yeast two-hybrid screen

pRS425 NUP49 (Leu selection) was transformed (using an alkalication yeast transformation kit, BIO 101, La Jolla, CA) into the yeast strain HF7c,
which contains the GAL1 UAS and TATA located upstream of the transcriptional
start site of the HI S3 reporter gene, and 3 copies of the GAL4 17-mer
consensus sequence and CYC1 TATA located upstream of a LacZ reporter
gene. For the library screen, a GAL4/BD yeast genomic library within the
plasmid pGBT-CYH (Trp selection) (obtained from Dr. Stan Fields, University of
Washington, Seattle, WA) was transformed into the pRS425 NUP49 containing
HF7c yeast.
-100,000 transformants were screened, 286 of which were selected on
-Trp-Leu-His 5 mM 3-aminotriazole (3-AT) CSM drop-out media, and were
subsequently tested for LacZ reporter gene transcription by the (3galactosidase colony filter assay. Colonies that turned blue were grown in -Trp
liquid media to cure the yeast of the pRS425 NUP49 bait plasmid according to
a procedure by Lundblad (1989). Liquid cultures were then restreaked on -Trp
drop-out plates and subsequently replica plated to -Trp-Leu drop-out plates.
Colonies that die on the -Trp-Leu plates but survive on -Trp contain only the BD
library plasmid. These colonies were then retested by the |3-galactosidase
colony filter assay to determine whether reporter gene activation was
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dependent upon the bait plasmid. Plasmids from potential bait dependent
colonies that did not turn blue, were isolated by a procedure described by
Hoffman (1993). Recovered library plasmids were retransformed into: HF7c
(negative control), HF7c + pRS425 (NUP49 absent, negative control) and HF7c
+ pRS425 NUP49 (positive control). Alternatively, potential bait dependent
colonies, that did not turn blue, were retransformed with pRS425 and pRS425
NUP49 separately. Transformants were tested with the B-galactosidase
colony filter assay to confirm the library plasmids ability to activate NUP49
dependent reporter gene transcription.

9. Aptamer 1 and aptamer 2 mobility shift assays

RNA aptamers 1 (32 nt) and 2 (31 nt) and the suc-Rev34_50-AAAAR-am
peptide were synthesized at the DNA/RNA/Protein synthesis facility at the
Beckman Research Institute of the City of Hope (Duarte, CA). Aptamers 1 and
2 were resuspended in modified TE (10 mM Tris pH 7.5, 0.1 mM EDTA) and 5’
end labeled using a forward reaction procedure described by Tabor (1987).
The reaction volume was 30 ^il and each sample contained: 10 mM MgCl2,
50 mM Tris-CI pH 7.5, 5 mM DTT, 50 j.ig/ml BSA, 20 units T4 polynucleotide
kinase, 50 pmols of [y-^P] ATP (3000 Ci/mmol), and 50 pmols of synthetic
RNA. The reaction was incubated at 37 °C for 60 minutes and stopped by
addition of 1 jliI 0.5 M EDTA. Samples were subsequently purified on G-25
Sephadex Quick Spin columns (Boehringer Mannheim, Indianapolis, IN).
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Following purification the samples were extracted with phenol-chloroform (1:1)
and chloroform, ethanol precipitated, and resuspended in TE.
pTZCCmt was derived from pTZU6+27CCmutant (mt) (obtained from Dr.
David Engelke, University of Michigan Medical School, Ann Arbor, Ml) by deletion
of the U6 promoter and 27 additional base pairs. The parent plasmid was
digested with Sal I and EcoR I and the resulting overhanging ends were filled in
with DNA polymerase I Klenow fragment. The vector was then purified in sea
plaque agarose and subjected to in-gel ligation with T4 DNA ligase. The
resultant plasmid was linearized with Xba I and unlabeled transcripts were
synthesized using 1.2 ^g of linearized template in a Megashortscript reaction
(using a Megashortscript kit purchased from Ambion Inc., Austin, TX). The
transcription was performed at 37 °C for 4 hrs, resulting in synthesis of a 48 nt
product. The sample was extracted with phenol-chloroform (1:1) and
chloroform, ethanol precipitated and resuspended in TE.
RNA-protein gel shift assays were performed at room temperature using
the protocol described by Daly et al. (1993a) with some modifications. The
binding reaction volume and buffer are as described in section 2.B.5, with the
exception that 1.5 |.ig BSA was added to each sample and 10 jug tRNA was not
included in the competition experiments. Labeled and unlabeled RNAs were
heated at 85 °C for 4 min and cooled on ice for 5 min. Then labeled aptamers
were incubated in the presence or absence of suc-Rev34_50-AAAAR-am
peptide. Competition experiments included unlabeled synthetic aptamers
(specific competitor) or unlabeled CCmt RNA (nonspecific competitor). Binding
was allowed to proceed for 30 minutes to 1 hr at 25 °C. Gel loading is as
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described in section 2.B.5. Gels were electrophoresed for 5 minutes at 15 mA
1 hr at 5 mA, and then 30 to 60 min at 15 mA, with subsequent drying and
exposure for autoradiography.

10. Modified aptamer 1 and aptamer 2 mobility shift assays

Modified aptamers 1 and 2 DNA oligo templates (1-5’-GGCCTGTATC
TGCAGCCGAAGCTGTGTCCAGACCCTATAGTGAGTCGTATTA-3’; 2-5’GGCC
TGTATCTC AAG C GT C ATTGACG C GAGTC CAGAC C CTATAGT GAGTCGIATTA-3’)
and unlabeled RNAs were obtained from Dr. Yuan Chen (Beckman Research
Institute of the City of Hope, Duarte, CA). Labeled modified aptamers were
obtained by performing in vitro transcription for 2 hrs at 37 °C. The reaction
volume was 50 fxl and the mixture contained: 500 ng modified aptamer 1 or 2
oligo template, 500 ng T7 primer (5’-TAATACGACTCACTATAG-3’), 1x New
England Biolabs T7 polymerase buffer [40 mM Tris-HCL pH 7.9, 6 mM MgCl2,
2 mM Spermadine, 10 mM DTT], 40 units RNase inhibitor, 2 mM ATP, 2 mM
GTP, 2 mM CTP, 0.25 mM UTP, 20 nCi [a-32p] UTP (800 Ci/mmol) and 100
units of T7 RNA polymerase. 40-100 units of DNase 1 were added after the
transcription reaction and incubation was continued for an additional 15 min at
37 °C. The reactions were stopped with 50 jliI of 2x loading buffer (containing
95% formamide, 0.025% xylene cyanol, 0.025% bromophenol blue, 0.5 mM
EDTA, 0.025 % SDS; Ambion recipe), heated for 2 minutes at 85 °C and loaded
onto a 10% TBE 8 M urea polyacrylamide gel for purification. The 35 nt
(modified aptamer 1) and 39 nt (modified aptamer 2) RNA bands were
identified and excised. RNAs were eluted in 400 j.il elution buffer (0.5M
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NH4(OAC)2, 1 rnM EDTA, 0.2% SDS; Ambion recipe) at 37 °C overnight.
Following elution the samples were added to 0.22 }.im 2.0 ml Spin-X centrifuge
tube filters (Corning Costar Corp., Acton, MA) and centrifuged at 14,000 rpm for
4 min. The flow-through was extracted with phenol-chloroform and chloroform,
then isopropanol precipitated and resuspended in TE. Incorporated 32p cpm
was determined by scintillation counting.
RNA protein mobility shift assays were performed as described in
section 2.B.9 except for incubation for 15 min at 25 °C and omission of tRNA.

11. RBE aptamer 6a-ribozyme mobility shift assays

pTZRBE-rbz was derived from pTZU6+27RBE-mt env ribozyme (rbz)
(see 2.B.5) using the same procedure described for subcloning the pTZCC-mt
from pTZU6+27CCmt in section 2.B.9. pTZRBE-rbz was linearized with Hind III
and 4.4 jiig of linearized template were used to transcribe unlabeled RNAs by
the same procedure used to obtain unlabeled pTZCC-mt (section 2.B.9),
resulting in synthesis of a 154 nt product. Labeled RBE aptamer-rbz was
transcribed using 1 (iig of linearized template in a T7 Maxiscript reaction (using
a Maxiscript kit purchased from Ambion Inc., Austin, TX), modified by addition of
[o-32p] UTP (20 nCi, 800 Ci/mmol) and 62,5

total cold UTP. The

transcription was performed at 37 °C for 4 hrs, and the template was removed
by addition of 2 units DNase I with subsequent incubation at 37 °C for 15 min.
The sample was gel purified as described in section 2.B.10 except 20 ^il 2x
loading buffer was added to the sample prior to loading, and a 154 nt product
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was isolated. Unlabeled and labeled samples were extracted with phenolchloroform and chloroform, then ethanol precipitated and resuspended in TE.
Radioactive cpm were determined by Cerenkov counting.
Mobility shift assays were performed at 25 °C using a protocol described
by Daefler et al. (1990) with some modifications. The binding reaction volume
was 10 f.d and each sample contained: 7.5 ^g BSA, 10 units RNase inhibitor,
60 mM NaCI, 12 mM Hepes (pH 7.9), 12 mM dithiothreitol, 4 mM Tris (pH 8.0)
and 4 mM MgCl2. Labeled RBE aptamer-rbz was incubated in the presence or
absence of Rev protein, unlabeled RBE aptamer-rbz (specific competitor) or
unlabeled CCmt (nonspecific competitor). Binding was allowed to proceed for
25 minutes, then the samples were loaded onto a 5% nondenaturing
polyacrylamide gel, electrophoresed and analyzed as described in section
2.B.5.

12. Mobility shift assay of aptamer 2 transcribed from a novel DNA
template

Single template transcription of aptamer 2 was performed in a 20 f.d
reaction volume at 37 °C for 2 hrs.

The reaction mixture contained: 1 |itg of

single DNA template coding for aptamer 2, 1x New England Biolabs T7
polymerase buffer [40 mM Tris-HCL pH 7.9, 6 mM MgCl2, 2 mM spermidine,
10 mM DTT], 20 units RNase inhibitor, 1 mM ATP, 1 mM GTP, 1 mM CTP, 1 mM
UTP, 30 f.iCi [a-32p] UJP (3000 Ci/mmol) and 25 units of T7 RNA polymerase.
2 units of DNase 1 were added after the transcription reaction and incubation
was continued for an additional 15 min at 37 °C. 20 ^il of 2x loading buffer
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(containing 95% formamide, 0.025% xylene cyanol, 0.025% bromophenol blue
0.5 mM EDTA, 0.025 % SDS; Ambion recipe) was added to the sample, which
was then heated for 2 minutes at 85 °C and loaded onto a 10% TBE 8 M urea
polyacrylamide gel for purification. A 34 nt RNA band was identified and
excised. RNAs were eluted and extracted as described in 2.B.10. Radioactive
cpm were determined by scintillation counting.
RNA protein mobility shift assays were performed as described in
section 2.B.9. except binding was allowed to proceed for 15 minutes at 25 °C.
Samples were then loaded onto a 5% nondenaturing gel and electrophoresed
for 5 minutes at 15 mA, 30 minutes at 7 mA, and then 15 mA for approximately
1 hr, with subsequent drying and exposure for autoradiography.

CHAPTERS

RESULTS

A. Analysis of HIV-1 Rev protein-protein interactions

1. Isolation of HIV-1 Rev-yeast interacting factors

We utilized an in vivo approach, the two-hybrid system, (Fields & Song,
1989; Chien et a!., 1991) to study Rev protein-protein interactions (Fig. 8). The
plasmid pBTM116 was used to express the Rev protein, fused in frame to a
heterologous DNA binding protein LexA (pBTM116 LexA/Rev). This plasmid
was used to transform the yeast strain, CTY10-5d, that contains a binding site
for LexA (the LexA promoter) located upstream of a p-galactosidase (LacZ)
reporter gene. CTY10-5d yeast containing the LexA/Rev fusion construct were
transformed with three yeast genomic plasmid libraries, constructed by S.
Fields and colleagues (Chien et al., 1991). These hybrid libraries have
genomic segments of DNA cloned into a BamHI site next to the acidic GAL4
activation domain (GAL4/AD) of the plasmid pGAD, and differ from each other
only by the reading frame of the BamHI site.

Using the different libraries

allowed for the three possible reading frames of the yeast genome to be
efficiently screened. Yeast cells containing double transformants were grown
on media selective for both plasmids. Sequences fused next to the GAL4/AD
that encoded a protein that could bind to Rev formed a bridge between LexA
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and the GAL4/AD allowing for binding and activation of transcription of the
reporter gene LacZ. LacZ transcription was tested by an in situ
(3-galactosidase assay. Forty two library clones, that showed Rev-dependent
reporter activation, were obtained from screening =200,000 colonies. DNA
sequencing of the GAL4/AD-library fusion joint allowed for identification of
sequences coding for potential Rev-interacting factors.

2. HIV-1 Rev interacts with the yeast nucleopore protein NUP100

One Rev-interacting clone, VY53, whose fusion joint was sequenced
was identified as being the 959 aa yeast nucleoporin, NUP100. aa 19-959 of
NUP100 were found to be in frame with the GAL4/AD. NUP100 is a member of
a family of five yeast nucleoporins containing amino terminal GLFG repeating
motifs, separated by serine, threonine, glutamine and asparagine rich
segments (Wente et al., 1992). The four other family members are known as
NUP49, NUP57, NUP116 and NUP145 (Wente & Blobel, 1994; Fabre et al.,
1994; Grandi et al., 1995). Although these nucleoporins have similar regions
within their amino termini, the carboxyl terminal residues of some diverge.
NUP100’s carboxyl terminal region contains basic residues (isoelectric point
9.38), and a nucleoporin RNA binding motif (NRM) has been localized to aa
807-955 (Fabre et al., 1994).
Having identified a Rev-interacting protein, we wished to determine
which regions of NUP100 were involved with the Rev interaction. To
accomplish this, domain analyses using the two-hybrid system were initiated
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(Fig. 9). The aa 19-583 encoding segment containing 29 GLFG repeating
motifs and the segment encoding aa 611-959 (containing no GLFG repeats)
were separately cloned in frame with the GAL4/AD of the plasmid pGAD424,
and tested for LexA/Rev interaction. Rev-dependent reporter gene activation
was found only with the construct containing the amino terminal region bearing
multiple GLFG repeats.
With numerous repeats present within NUPIOO’s amino terminus, we
were interested in testing whether some or all were necessary for Rev
interaction (Fig. 9). Therefore subregions of NUP100 containing 2 to
25 repeats were cloned in frame with the AD of the pGAD424 vector and
assayed for LexA/Rev interaction. A subregion from aa 121-583 containing 25
repeats was found to interact with Rev as well as the full amino terminus of
NUP100. Rev interaction was not detected with other subregions tested,
except for a weak interaction found with aa 121-383 of NUP100, which
contained 14 repeats.

3. HIV-1 Rev interacts with the yeast nucleoporin NUP49

Two Rev-pGAD yeast library interacting clones (VY54 and VY63) were
found to contain part of the XRN1 gene, (Larimer & Stevens, 1990) also known
as KEM1 (Liu & Gilbert, 1994), SEP1 (Tishkoff et al., 1991), RAR5 (Kipling et al.,
1991) and DST2 (Dykstra et al., 1991), located on the noncoding strand (the
XRN1 gene product is a multifunctional protein which promotes homologous
pairing and strand exchange during recombination); however, the coding
strand had stop codons immediately adjacent to the GAL4/AD (Fig. 10). Hence
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Figure 9. Rev Interacts with the Nucleoporin NUP100 In Vivo. pGAD424
plasmids containing various subdomains of NUP100 were tested for
interaction with LexA/Rev in the two-hybrid system. + or - indicates the
presence or absence of Rev interaction, aa tested are shown above the
subdomains. The numbers within the subdomains or directly to their left
indicate the amount of GLFG repeats present. NUPIOO’s domain structure
was adapted from Fabre et al. (1994).
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the protein synthesized was not a hybrid fused with the GAL4/AD and was also
not under the control of the pGAD plasmid promoter. One possibility was that
these clones encoded a Rev-interacting protein expressed from its own
promoter and which also contained an acidic activation motif. We tested this
hypothesis by subcloning the region of overlap between the two isolates into
the plasmid pRS425 (Christianson et al., 1992), a standard yeast non
expression vector, which does not contain a promoter next to its multicloning
site, and does not code for a transcriptional AD. When tested in the two-hybrid
system, the construct showed Rev-dependent activation of the LacZ reporter.
An additional sequence comparison search of the upstream region of
iheXRNI gene through NIH BlastN, showed that our clones contained the
entire NUP49 gene, a previously characterized yeast nuclear pore protein.
Subsequently we found three more Rev-interacting clones that contained the
entire NUP49 gene. NUP49, has 472 aa and is an acidic protein (isoelectric
point 5.94); the majority of the acidic residues are contained in its C-terminal
region (~ aa 258-472) which could potentially act as an activation domain. Like
NUP100, NUP49 is also a member of the GLFG family of nucleoporins (Wente
et al., 1992). Both proteins have similar GLFG repeats in their amino terminal
regions, but their carboxyl terminal regions vary from one another.

4. NUP49,s C-terminus functions as an AD in the two-hybrid system

NUP49 contains 13 GLFG repeats in its N-terminal region and a heptad
repeat pattern, with hydrophobic amino acids at position 1 and 4 of a 7 residue
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long repeating sequence, in its C-terminal region (Wimmer et al., 1992). GLFG
repeats are thought to be protein docking sites on nucleoporins (Radu et al.,
1995) and heptad repeats have been shown to be involved in coiled-coiled
protein interactions (Lupas et al., 1991). Based on the domain analysis with
NUP100 we reasoned that the GLFG repeat domain of NUP49 would also be
involved with Rev interaction. To test this hypothesis, C-terminal NUP49
deletion mutants were produced and tested using the two-hybrid system. The
polymerase chain reaction was used to isolate the NUP49 gene from the
pRS425 NUP49 plasmid, with subsequent restriction digestion and cloning of
various deletion fragments in frame with the AD of the pGAD424 vector.
When these deletion mutants were tested for their interaction with Rev,
some unexpected results were observed (Fig. 11A-C). The segment of aa 5431 of NUP49 showed a positive result for Rev interaction. However, the aa 5243 segment from NUP49’s amino terminus, containing all of its repeating
GLFG units did not interact with Rev in the two-hybrid system. These results
can be explained by the following possibilities. First, the GLFG region of
NUP49 may not interact with Rev, NUP49 may use its carboxyl terminus for this
purpose. However, based on the results with NUP100 this explanation
seemed unlikely. Second, the GLFG repeats of NUP49 may interact with Rev
only in the presence of its carboxyl terminus, which may facilitate proper folding
of the Rev interacting GLFG amino terminal region. However, this reasoning is
problematic, since the carboxyl terminus of NUP100 and NUP49 diverge, yet
NUPIOO’s GLFG repeats form a proper conformation for interaction. A third
explanation could be that NUP49,s GLFG repeats mediate interaction with Rev
in the context of the wild type protein, but not when its amino terminal repeats
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Figure 11. HIV Rev-NUP49 In Vivo Interactions. A-C) pGAD424 plasmids
containing various subdomains of NUP49, fused in frame to the GAL4/AD, were
tested for interaction with LexA/Rev in the two-hybrid system. D-F) p49AD203
was derived by substitution of NUP49’s C terminus for the GAL4/AD of
pGAD424. p49AD203 alone or fused in frame with the GLFG domain of NUP49
or NUP100 was then tested for interaction with LexA Rev in the two-hybrid
system. + or - indicates the presence or absence of Rev interaction, aa tested
are shown above the subdomains. NUP49’s domain structure was adapted
from Wente and Blobel (1994).
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are fused with the GAL4/AD. This may be due to the ability of NUP49’s carboxyl
terminus, in native conformation, to act as a stronger transcriptional activator
than the GAL4/AD.
Further two-hybrid domain analysis was therefore undertaken to better
understand which of these possibilities could account for regions of NUP49
involved with Rev protein-protein interaction (Fig. 11D-F). The pGAD424 vector
was modified by replacement of the sequences coding for the GAL4/AD with
those coding for the carboxyl terminal acidic residues of NUP49 (aa 258-472),
giving rise to the plasmid p49AD203. This was done for the purpose of testing
whether the carboxyl terminus alone could interact with Rev, and also whether it
could indeed function as an AD in the two-hybrid system. The aa 19-583
segment of NUP100, and the aa 5-290 segment of NUP49, containing
complete GLFG containing regions were cloned in frame with NUP49,s
carboxyl terminus within the p49AD203 vector. When these constructs were
tested by two-hybrid analysis, NUP49’s carboxyl terminus alone showed no
interaction with Rev, however NUPIOO’s and NUP49’s amino terminal regions
were found to interact with Rev. Therefore, the GLFG repeat regions of both
nucleoporins mediate their interaction with Rev, and NUP49’s carboxyl
terminus is able to function as a transcriptional activation domain in the twohybrid system.
5. NUP100 and NUP49 interact with the nuclear export sequence of
HIV-1 Rev

Having determined the regions of the nucleoporins involved with Rev
interaction, it became of interest to define domains of Rev that confer
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nucleoporin binding. We wished to determine whether Rev domains important
for nuclear import and/or export mediated our observed results. Therefore,
pBTM116 LexA vectors with Rev mutants were constructed and tested for
nucleoporin interaction in the two-hybrid system (Fig. 12). Constructs coding
for LexA/Rev and a LexA/truncated Rev protein (deletion of aa 1-52) lacking
Rev’s NLS, were found to interact with both NUP49 and NUP100. However an
interaction with the nucleoporins was not detected between LexA/RevM10,
mutated in it’s NES. These results support Rev NES mediated nucleoporin
interaction, and eliminate the Rev NLS as being important for these
interactions within the two-hybrid system.

6. Expression and purification of six-His tagged NUP100 and NUP49

Having demonstrated the interaction of Rev with NUP100 and NUP49
using the two-hybrid system, we wished to test the ability of Rev and the
nucleoporins to interact directly in v/'fro without being fused to LexA or the
GAL4/AD. To test in vitro protein binding, both nucleoporins had to be obtained
in a pure form. Therefore we chose to use the QIAexpress system, from
QIAGEN Inc. for this purpose. This system is based on the selectivity of a
nickel nitrilo-tri-acetic acid (Ni-NTA) resin for proteins tagged with six histidine
(His) residues (Janknecht et al., 1991).

NUP49 and the amino terminus of

NUP100 (aa 19-583) were cloned in frame adjacent to a six-His tag of the
QIAexpress pQE30 expression vector. These constructs were then
transformed into bacteria, with subsequent bacterial growth and induction of
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Figure 12. NUP100 and NUP49 Interact with the Rev Nuclear Export Sequence.
To delineate the regions of Rev that interacted with NUP49 and NUP100,
LexA/Rev, LexA/truncated Rev or LexA/RevM10 were tested for interaction with
the GLFG domain of NUP100 [pGAD424( 19-583)] or NUP49 [pRS425 NUP49]
in the two-hybrid assay. + or - indicates the presence or absence of interaction,
aa of Rev are shown above the various constructs.
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recombinant protein expression. Recombinant N-terminal six-His affinity
tagged nucleoporins were then bound to a Ni-NTA resin under denaturing
conditions, refolded on the column and eluted (Fig. 13).

7. HIV-1 Rev’s interaction with NUP100 and NUP49 may be weak or
indirect

Rev protein interacts with RRE-containing HIV-1 mRNAs within the
nucleus and transports them through the nucleopore to the cytoplasm. In this
process Rev interacts with RNA and may also interact directly with the
nucleopore to facilitate export. In an effort to test Rev’s ability to interact with
RNA and nucleopore proteins directly in vitro, mobility supershift and ligand blot
assays were performed.
In the mobility super shift assays we chose to use a radiolabeled high
affinity Rev binding ligand evolved by SELEX, known as RBE aptamer 6a (Tuerk
& MacDougal-Waugh, 1993) (Fig. 4D), to study Rev interactions. Radiolabeled
RBE aptamer 6a incubated with Rev produced a detectable shift in the banding
pattern (Fig. 14). However, incubation of the aptamer with Rev in the presence
of increasing ratios of six-His tagged NUP49 to Rev protein showed no
detectable supershift. No supershift was detected when radiolabeled RRE
was incubated with Rev in the presence of six-His tagged NUP49 or NUP100
(aa 19-583) (data not shown).
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Figure 14. NUP49-Rev Interaction Not Detectable by In Vitro Mobility Supershift
Assays. Radiolabeled RBE aptamer 6a was incubated alone (lane 1) or with
various concentrations of Rev protein: 1.05 f.iM (lane 2), 2.1
(lane 3),
0.525 |iM (lane 4), 0.21
(lane 5). After Rev binding, 4.2 (.iM (lane 4) and
5 jaM (lane 5) NUP49 was added and given time to bind. The samples were
loaded onto a 5% nondenaturing polyacrylamide gel, electrophoresed, dried
and exposed for autoradiography.
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Figure 13. Expression and Purification of NUP49 and NUP100. A) Initial
detection of expressed proteins. 1 ml of uninduced and induced bacteria was
pelleted and resuspended in 50 f.il and 100 jxl 5X SDS-PAGE sample buffer
(15% 2-mercaptoethanol, 15% SDS, 1.5% bromophenol blue, 50% glycerol)
respectively. The samples were heated for 7 min at 97 °C and subsequently
microcentrifuged for 1 min. 20 (ul of each sample was loaded onto a 10% SDSPAGE gel. Bands were then visualized by coomassie blue staining.
B) NUP100 and C) NUP49 elution profiles were visualized by adding 7 ^il 5X
SDS-PAGE sample buffer to 30 [.il aliquots of the indicated numerical elution
fractions. The samples were heated for 10 min at 37 °C, loaded onto a 10%
SDS-PAGE gel, which was subsequently stained with coomassie blue.
Controls (CTLS) are from previous purification experiments in which elution
was performed under denaturing conditions.
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After numerous unsuccessful attempts to show a direct interaction
between Rev and the nucleoporins with supershift assays, we utilized a ligand
blotting approach to look for interactions. Decreasing amounts of six-His
tagged NUP49 and NUP100 (aa 19-583) were bound to a nitrocellulose
membrane, followed by incubation with Rev and radiolabeled RRE (Fig. 15). A
signal was detected between NUP100 incubated with Rev and radiolabeled
RRE. However this signal was also detected when NUP100 was incubated
with transdominant Rev (which did not interact with NUP100 in vivo) and
radiolabeled RRE, or radiolabeled RRE alone. Therefore the presence of the
signal appears to indicate an interaction between NUP100 and the RRE. This
RNA interaction is most likely non-specific. Since no shift between the amino
terminus of NUP100 and radiolabeled RRE (without Rev) was observed in
mobility shift assays that included excess amounts of non-specific competitor
RNA (data not shown) we hypothesize that the N-terminal domain of NUP100
can mediate non-specific RNA interactions. Overall the lack of detectable
interaction between the nucleoporins and Rev in mobility supershift and ligand
blot assays in vitro, led us to hypothesize that their interaction in vivo may be
weak or indirect.

8. Screening for cofactors that bridge HIV-1 Rev’s interaction with
NUP100 and NUP49

The absence of a demonstrable direct interaction between Rev and the
nucleoporins led us to investigate whether the interactions we observed
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utilizing the two-hybrid system were indirect. Rev may interact with one or more
cellular factors that bridge Rev’s interaction with the nucleopore, thereby
allowing for Rev-mediated RNA export. The absence of such factors in our in
vitro binding assays could explain our negative results.
In order to identify potential bridging factors we chose to use NUP49 as
a bait protein in a two-hybrid screen of the yeast genome. Since NUP49 has
both a Rev-interacting GLFG repeat amino terminal region and an acidic
carboxyl terminus that can act as a transcriptional activation domain; it could
not be cloned in frame with LexA (as is usually required for two-hybrid bait
proteins). A LexA/NUP49 fusion protein would activate transcription without a
library partner, eliminating its use to screen for a interaction partner from a AD
library. Therefore we chose to use a reverse two-hybrid screen in which wild
type NUP49 could be used to screen a GAL4/BD library (instead of the standard
AD library). A high background of false positives is expected from this library
(Dr. Stan Fields, personal communication), since approximately 1% of the
yeast genome codes for acidic protein regions that have the potential to act as
a transcriptional AD when fused to a BD.
To facilitate identification of true positives in our reverse two-hybrid assay
a dual reporter yeast strain (Fig. 16), and multiple replica plating steps were
utilized. The plasmid pRS425 NUP49 was used to express wild type NUP49.
This plasmid was used to transform the yeast strain, HF7c, which contains the
GAL1 DAS and TATA located upstream of the transcriptional start site of the
HIS3 reporter gene, and 3 copies of the GAL4 17-mer consensus sequence
and CYC1 TATA located upstream of a LacZ reporter gene. For the library
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screen, a GAL4/BD yeast genomic library within the plasmid pGBT-CYH
(constructed by Fields, and colleagues) was transformed into the pRS425
NUP49 containing HF7c yeast. Double transformants containing potential
interacting factors were selected by their ability to activate both His3 and LacZ
reporters.
Two hundred and eighty six library clones, out of

00,000 colonies

screened, showed growth in the absence of His. One hundred and eighty four
of these colonies were found to activate the LacZ reporter as determined by the
p-galactosidase assay. One hundred and seventy six of these were able to
activate the latter reporter independent of the pRS425 NUP49 plasmid,
resulting in a total of 278 false positives out of 286 isolates. Of the remaining
8 colonies, the pRS425 NUP49 plasmid could not be dropped out in 2 of them
(potentially their selectable markers were integrated). One isolate died during
the process of sorting though multiple other potential NUP49 interacting
clones. Two were found to be variably white or blue in repeated
p-galactosidase assays, and should not have been included in the original 184
colonies thought to activate the dual reporters. Three were unable to activate
the LacZ reporter gene without the pRS425 NUP49 plasmid as would be
expected for a true positive, but were also unable to activate the LacZ reporter
when either NUP49 was retransformed into the yeast or the library plasmid
was isolated and transformed into pRS425 NUP49 containing yeast. These
last three colonies were therefore either false positives or true positives whose
library genes had been altered during the multiple steps of the reverse twohybrid assay. The latter hypothesis is being tested by Dr. Lisa Scherer
(Beckman Research Institute of the City of Hope, Duarte, CA).
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B. Analysis of HIV-1 Rev protein-RNA interactions

1. Specific interaction of Rev protein with a class I RBE aptamerribozyme

It has been suggested that intracellular interaction of Rev protein with an
anti HIV-1 RBE decoy-ribozyme, enhanced this dual inhibitory agents function in
vivo (Yamada et al., 1996). However an in vitro interaction between Rev and
such molecules has not been shown. Linking a highly structured sequence of
a ribozyme to a RNA molecule that interacts with Rev, may affect the ability of
that interaction to occur. To investigate this possibility a ribozyme linked to a
class I RBE aptamer, known to interact with higher affinity to Rev than the RBE
(Tuerk et al., 1993), was examined for its ability to interact with Rev protein.
Radiolabeled RBE aptamer 6a (Tuerk & MacDougal-Waugh, 1993;
Jensen et al., 1994) (Fig. 4D) linked to a mutant e/?v ribozyme (Konopka et al.,
1998) was tested for its ability to specifically interact with Rev protein in
competition mobility shift assays (Fig. 17). The incubation of Rev protein with
the RBE aptamer-ribozyme produced a detectable shift in the banding pattern
compared to the RBE aptamer-ribozyme alone, showing that an interaction is
indeed possible. The addition of unlabeled RBE aptamer-ribozyme (specific
competitor) decreased the presence of the shift, while unlabeled CCmt RNA
(non-specific competitor; Fig. 4E) had no affect on the shift. The interpretation
of these results is that Rev protein is able to interact in a specific manner with a
RBE aptamer-ribozyme molecule.
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2. Modified Rev basic domain peptide interacts specifically with
modified class I and class III RBE-aptamers

RRE and RBE RNA decoys expressed in HIV-1 infected cells have been
shown to be effective antiviral therapeutics (Bevec et al., 1994; Bahner et al.,
1996; Bauer et al., 1997; Inouye et al., 1997). These molecules are believed to
function by decoying Rev protein from RRE-containing HIV-1 mRNAs. The use
of RNA molecules that interact with higher affinity to Rev than the wild type RBE
may therefore prove to be more effective antiviral agents. RBE aptamer 1
(class III) and RBE aptamer 2 (class I) (Fig. 4B &C) are two Rev binding ligands
isolated by SELEX, that have been shown to interact with higher affinity to Rev
than the wild type RBE (Giver et al., 1993a; Giver et al., 1993b; Symensma et al.,
1996). If these molecules are to be evaluated in cells for their ability to inhibit
Rev function and HIV-1 replication, their interaction with Rev needs to be highly
specific. To evaluate the nature of these interactions mobility shift and
competition mobility shift assays were used.
Radiolabeled RBE aptamer 1 and RBE aptamer 2 were tested for
interaction with a modified Rev basic domain peptide (suc-Rev34_50-AAAARam peptide), known to interact specifically with the RBE (Tan et al., 1993).
Increasing concentration of suc-Rev34-50-AAAAR-am peptide in the presence
of constant amounts of radiolabeled aptamers showed that both aptamers
were able to interact with modified Rev peptide, however aptamer 2 appeared
to interact with a significantly higher affinity (Fig. 18).
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The specificity of these interactions were then investigated using
competition experiments (Fig. 19 and Fig. 20). Incubation of suc-Rev34_50AAAAR-am peptide with the radiolabeled RBE aptamer 1 and RBE aptamer 2
produced a detectable shift in the banding pattern compared to their respective
RNAs alone. Addition of respective unlabeled RBE aptamers (specific
competitors) decreased the presence of the shift, while unlabeled CCmt RNA
(non-specific competitor) had no affect on the shift of RBE aptamer 2, but
decreased the shift of RBE aptamer 1. The interpretation of these results is
that modified Rev peptide is able to interact in a specific manner with RBE
aptamer 2, but not with RBE aptamer 1.
One possible explanation for this observation was that the RBE-like
motif of RBE aptamer 1 and RBE aptamer 2 was not forming a stable structure
in vitro. In aptamer 1 this would be expected to decrease specific interaction
since it is a class III molecule and its RBE-like motif is its only source of
specific interaction with modified Rev peptide. However aptamer 2, being a
class I molecule, would still be able to show a specific interaction if its RBE-like
motif was not forming a stable structure, as long as its second Rev binding
motif was able to form. A computer RNA folding analysis was therefore
performed to ascertain whether the RBE-like motifs of both aptamers were
predicted to form. As hypothesized for both aptamers, the RBE-like motifs were
not predicted to form, but aptamer 2’s second motif, consisting of two bulged U
residues, was predicted to form (Fig. 21A & C).
Based on the above information, we reasoned that changes in the
aptamer sequences that stabilized the RBE-like motifs should allow for specific
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interaction of aptamer 1 with suc-Rev34_50-AAAAR-am peptide. Aptamer 1 and
aptamer 2 were therefore modified by lengthening the stems below their RBElike motifs with an additional three base pairs. In addition, aptamer 1’s tri
nucleotide loop was changed to a tetra-loop, a modification that should
strengthen the formation of the stem below it. Aptamer 1 ’s stem below the
tetra-loop was also shortened by three base pairs. (Fig. 21B & D).
The modified aptamers interactions with suc-Rev34_50-AAAAR-am
peptide were retested. Increasing concentrations of the peptide in the
presence of constant amounts of radiolabeled modified aptamers showed that
both aptamers were able to interact with suc-Rev34_50-AAAAR-am peptide.
Qualitatively, it appears that the modifications have allowed for both aptamers
to interact with similar affinity for suc-Rev34_50-AAAAR-am peptide
(Figs. 22A & B).
Specific interactions of the modified aptamers to suc-Rev34_50-AAAARam peptide were then tested utilizing competition experiments (Figs. 23A & B).
Incubation of suc-Rev34_50-AAAAR-am peptide with radiolabeled modified
RBE aptamer 1 and modified RBE aptamer 2 produced a detectable shift in the
banding pattern compared to their respective RNAs alone. Addition of
unlabeled modified RBE aptamers (specific competitors) decreased the
presence of the shift, while unlabeled CCmt RNA (non-specific competitor) had
no affect on the shifts of both modified aptamers. These results show that the
modifications made in aptamer 1 now allow its specific interaction with sucRev34_50-AAAAR-am peptide. Based on the above results and the computer
RNA folding analysis (Fig. 21B & D) it appears that the change in the specific
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interaction of modified aptamer 1 is due to stabilization of its RBE-like motif,
and this motif is most likely stabilized in modified aptamer 2 as well.

3. Transcription of RBE aptamer 2 from propane diol terminated
single DNA templates gives rise to a functional aptamer in vitro

Experiments were undertaken to evaluate the feasibility of using novel
single DNA templates for T7 polymerase transcription of functional RNA in vitro.
In this method the single DNA template folds on itself to create the double
stranded T7 promoter site and a looped out single stranded region contains
the coding sequence for an RNA molecule of interest (Fig. 7B). RBE aptamer 2
was chosen to be encoded by the template for the purpose of testing its ability
to interact with modified Rev peptide, post transcription, in mobility shift assays.
Preliminary results (data not shown) revealed a potential flaw in the
design of the templates, in that the length of RNA produced included
readthrough of the T7 promoter strand. We hypothesized that the inclusion of
abasic carbon residues at the end of the coding loop may allow for the
polymerase to fall off the template, thereby allowing transcriptional termination.
To test this possibility ten propane diol units were included at the end of the
coding loop for aptamer 2 within the template (Fig. 7C). Subsequent in vitro
transcription from this template revealed that the propane diol units resulted in
transcriptional termination and an appropriate sized RBE aptamer 2 molecule
was obtained (Fig. 24).
Radiolabeled RBE aptamer 2 transcribed from the propane diol
terminated single DNA template was tested for specific interaction with
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suc-Rev34-50-AAAAR-am peptide in a competition mobility shift assay (Fig. 25).
Incubation of suc-Rev34-50-AAAAR-am peptide with radiolabeled RBE aptamer
2 produced a detectable shift in the banding pattern compared to RBE aptamer
2 RNA alone. Addition of unlabeled RBE aptamer 2 (specific competitor)
decreased the presence of the shift, while unlabeled CCmt RNA (non-specific
competitor) had no affect on the shift. These results demonstrated that RBE
aptamer 2 produced from the propane diol terminated single DNA template is
able to interact in a specific manner with modified Rev peptide, and validate
the use of these templates to produce functional RNAs in vitro.
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CHAPTER4

DISCUSSION

A. Rev protein-protein interactions

1. The nuclear pore complex and cellular transport

The nucleopore complex (NPC) is ~66 MDa in yeast and «125 MDa in
amphibians. Although their sizes differ, their electron microscope structures
appear similar. The NPC is comprised of 50 to 100 proteins termed
nucleoporins (NUPs) (Rout & Blobel, 1993; for reviews see Doye & Hurt, 1997;
Fabre & Hurt, 1997; Nakielny & Dreyfuss, 1997; Pante and Aebi, 1997). Based
on their primary structure four nucleoporin families in yeast have been
identified to date. Three of the families have repeating FG units including:
XXFG (Stutzetal., 1995; Del Prioreetal., 1997), FXFG (Davis & Fink, 1990;
Wimmer et al., 1992; Loeb et al., 1993; Nehrbass & Blobel, 1996), and GLFG
repeats (Grand! et al., 1995b). The fourth family is characterized by the
absence of such repeats (Aitchison et al., 1995; Grandi et el., 1995a; Grandi et
al., 1995b; Hurwitz & Blobel, 1995; Pemberton et al., 1995; Nehrbass et al.,
1996; Zabel et al., 1996; Bastos et al., 1997). Multiple structural units
composed of the various nucleoporins have been defined including: a central
transporter flanked above and below with cytoplasmic and nuclear rings, and
surrounded by a multidomain spoke complex. Extending from the cytoplasmic
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ring are eight kinked filaments. Eight long filaments also extend from the
nuclear ring into the nucleus forming a nuclear basket that connects to a
smaller terminal ring (for reviews see Forbes, 1992; Hurt, 1993; Newmeyer,
1993; Davis, 1995; Goldberg & Allen, 1995; Pante & Aebi, 1996; Doye & Hurt,
1997).
The nuclear pore complex allows for passive diffusion of small
molecules and active transport of proteins and RNA. Active transport is signal
mediated (for reviews see Osborne & Silver, 1993; Gorlich & Mattaj, 1996; Nigg,
1997). Proteins bearing an NLS are transported into the nucleus by the
importin alpha/ importin beta complex.

Importin alpha functions as a NLS

receptor binding directly to the NLS protein, while importin beta functions to
dock this complex to the nucleopore allowing for energy dependent
translocation (Radu et al., 1995a; Rexach & Blobel, 1995; for reviews see Pante
& Aebi; Gorlich, 1997). Nuclear export is mediated by proteins that contain an
NES (for reviews see Gerace, 1995; Izaurralde & Mattaj, 1995; Fischer et al.,
1996; Nakielny & Dreyfuss, 1997). Analogous to NLS mediated transport, one
would expect proteins with an NES to interact with the nuclear pore, and
potentially with a receptor(s) that could mediate this interaction.

2. Rev interacts with the GLFG repeat regions of nucieoporins NUP49
and NUP100

We report identification of two yeast nucieoporins that interact with the
HIV-1 Rev protein. Rev protein is essential for viral replication (Feinberg et al.,
1986; Sodroski et al., 1986), and functions by regulating the selective
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nucleocytoplasmic transport and expression of HIV unspliced and singlyspliced RNA (Felber et al., 1989; Arrigo & Chen, 1991; D’Agostino et al., 1992;
Malim & Cullen, 1993). Rev has both an NLS (Kubota et al., 1989; Malim et al.,
1989b; Perkins et al., 1989; Venkatesh et al., 1990) and a NES (Fischer et al.,
1995; for review see Gerace, 1995; Wen et al., 1995) and shuttles between the
nucleus and the cytoplasm, allowing for multiple rounds of viral mRNA
transport (Kalland et al., 1994; Meyer & Malim, 1994; Richard et al., 1994;
D’Agostino etal., 1995; Stauber et al., 1995; Szilvay et al., 1995; Wolff et al.,
1995). Rev’s transport function has been recapitulated in Xenopus laevis
oocytes (Fischer et al., 1995; Pasquinelli et al., 1997) and yeast (Stutz &
Rosbash, 1994), leading to the speculation that factors facilitating Rev
mediated RNA export are conserved. Using the two-hybrid system (Fields &
Song, 1989; Chien et al., 1991) to search for factors in yeast involved in Rev
transport, we isolated two Rev binding nucleoporins, NUP100 and NUP49.
Both nucleoporins were not found to interact with the HIV-1 Vif protein or a
mutant form of Rev (RevMIO) in the two-hybrid assay, yet exhibited HIV-1 Revdependent reporter gene activation, showing that their interaction is specific.
Interestingly, NUP100 (Wente et al., 1992) and NUP49 (Wente et al.,
1992; Wimmer et al., 1992) are both members of the GLFG family of
nucleoporins . Three other family members exist in yeast, NUP57 (Grand! et
al., 1995b), NUP116 (Wente et al., 1992; Wimmer et al., 1992), and NUP145
(Fabre et al., 1994; Wente & Blobel, 1994). Members of this family are
characterized by the presence of several glycine (G), leucine (L), phenylalanine
(F), glycine (G), repeating units within their amino termini; however the carboxy
terminal regions of some diverge. NUP100, NUP116, and the N-terminus of
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NUP145 have basic isoelectric points (full length NUP145 is acidic), and each
contain a carboxy terminal RNP-1 RNA binding motif (Fabre et al., 1994).
NUP49 (acidic isoelectric point, Wente et al., 1992) and NUP57 (basic
isoelectric point) on the other hand have carboxyl terminal regions that are
predicted to form structures involved in protein-protein interaction, known as
coiled-coils (Wimmer et al., 1992; Grandi et al., 1995b). The coiled-coils form
due to the presence of a heptad aa repeat pattern, with most of the seven aa
positions being hydrophilic, except positions 1 and 4, which are hydrophobic
(Lupas et al., 1991; for review see Lupas, 1996).
With different motifs present in the nucleoporins we wished to determine
which of them were involved in Rev interaction. Two-hybrid domain analysis
allowed for localizing the Rev-interacting region of NUP100 to its amino
terminus containing the GLFG repeats. Since this was the only domain
NUP100 and NUP49 shared, we reasoned that this region would also mediate
NUP49’s interaction with Rev. Subsequent two-hybrid domain testing
confirmed our hypothesis.

3. Rev’s NES is essential for GLFG nucleoporin interaction in the
two-hybrid system

Having localized the regions of the nucleoporins involved in Rev
interaction, we wished to determine which regions of Rev mediated interaction
with both nucleopore proteins. We hypothesized it would either be Rev’s NLS,
involved in nuclear import, or its NES, involved in nuclear export. To test this
hypothesis we used the two-hybrid system to determine if both nucleoporins

136
would interact with the NES mt RevMIO or a truncated Rev mt lacking a NLS.
NUP100 and NUP49 were found to interact with wild type Rev and truncated
Rev, but not with RevMIO. Based on these results we infer that Rev interacts
with the GLFG domains of these nucleoporins using its NES, and we believe
that Rev nucleocytoplasmic transport of RRE-containing transcripts is
mediated by docking to multiple repeat containing sites within the nuclear pore
complex, two of which in yeast are NUP49, and NUP100.

4. Nucleoporins as docking sites in nucleocytoplasmic transport

Since Rev can mediate RNA transport in yeast (Stutz & Rosbash, 1994)
as it does in mammalian cells, it would be expected that Rev-yeast interacting
factors have mammalian homologues.

Radu et al. (1995b), described a rat

nucleoporin, NUP98, with sequence homology to the yeast nucleoporins
NUP49 and NUP100. This protein contains numerous GLFG and FG repeats,
and some FXFG repeats, and has been categorized as a vertebrate GLFG
nucleoporin family member. NUP98 in the presence of cytosolic extract was
found to interact with NLS substrate in vitro. Therefore it is believed to function
as one of many docking site nucleoporins involved in protein-protein
interactions during nucleocytoplasmic transport. Interestingly, the docking site
of NUP98 was localized to its amino terminal half, which contains its numerous
repeats. Radu suggested that the peptide repeat domains of NUP98 and other
nucleoporins form an array of sites for mediating docking of transport
substrate, and that import and export substrate travel through the nuclear pore
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by repeated docking and undocking reactions. Although it was speculated that
export substrate would interact with these nucleoporins, this was not shown.
Our results however support their hypothesis and implicate repeat containing
nucleoporins as docking sites for NES bearing transport factors in vivo.
Other groups have reported results similar to ours demonstrating the
importance of FG repeat containing nucleoporins for Rev and other NES
proteins in export. Hrip/Rab is a human XXFG nuclear pore-like protein that
was found to first interact with the NES of Rev (Bogerd et a!., 1995; Fritz et al.,
1995) and subsequently to other NES proteins in the two-hybrid system (Fridell
et al., 1996a; Fridell et al., 1996b; Fritz & Green, 1996) Overexpression of this
protein was found to enhance Rev export (Bogerd et al., 1995). Hrip/Rab was
reported to be located at the nuclear pore (Fritz et al., 1995), nucleoplasm (Fritz
et al., 1995; Bogerd et al., 1995) and nucleolus (Bogerd et al., 1995). Therefore
it has been suggested that it may bind Rev and direct it to the nuclear pore
(Bogerd et al., 1995). In addition, several other nucleoporins were found to
interact with NES proteins including Rev in the two-hybrid system. These
nucleoporins were from the all the repeat families, but not the family lacking
repeats (Stutz et al., 1995; Stutz et al., 1996; lovine & Wente, 1997; Neville et al.,
1997). Rev however, failed to interact with FXFG nucleoporins NUP1, NUP2,
and NSP1 (Stutz et al., 1996), but showed interaction with the FXFG nucleoporin
NUP153 (Fritz & Green, 1996). Some of the Rev binding nucleoporins have
been localized to regions of the nuclear pore complex in the nuclear basket,
nuclear membrane, and cytoplasmic fibrils (Fritz & Green, 1996). These
results also support Rev export being mediated by multiple docking sites to
nucleoporins as it travels through the pore.
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5. A role for NUP49 in protein import and RNA export

NUP49, and NUP57 have been localized to a nuclear pore subcomplex
(Grandi et al., 1993; Grandi et al., 1995b). Interestingly, all four proteins within
this subcomplex (NUP49, NUP57, NSP1, NIC96) contain heptad repeats, and
are essential for yeast viability. Mutation of the heptad repeat region of NIC96
inhibits its ability to coprecipitate with the other three core members. In
addition, mutations in the heptad repeats of NUP49 or NSP1 also inhibit NIC96
interaction (Grandi et al., 1995b). Two temperature sensitive mutants in the
heptad repeats of NUP49 have also been shown to block either nuclear import
of reporter protein, or poly (A)+ RNA export (Doye et al., 1994). NUP49 has also
been shown to have synthetic lethality with NSP1 (Wimmer et al., 1992; for
review see Doye & Hurt, 1995) and NUP133 (Doye et al., 1994), temperature
sensitive mutations of the latter nucleoporin have been shown to inhibit poly
(A)+ RNA transport. Clearly showing, NUP49 (or its interaction with
nucleoporins) is involved in both import and export.

6. A role for NUP100 in RNA export

NUPIOO’s role in export is intriguing. NUP100, NUP116, and NUP145
contain a RNP-1 RNA binding motif shown to interact with poly G RNA in vitro
(Fabre et al., 1994). Of the three proteins NUP145 alone is essential (Wente et
al., 1992; Fabre et al., 1994), depletion of NUP145 results in rapid nuclear poly
(A)+ RNA accumulation. Deletion of one of the nucleoporin RNA binding motifs
(NRM) from any of these proteins shows no growth defect, however deletion of
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all three NRM is lethal. Therefore, these regions appear to be functionally
redundant, and important for RNA export (Fabre et al., 1994). Interestingly,
NSP1 (NUP49 subcomplex member) shows synthetic lethality with NUP145,
and NUP116 (Wimmer et al., 1992). NUP100 on the other hand shows
synthetic lethality with NUP116 (Wente & Blobel, 1994), and the NES bearing
proteins implicated in RNA transport, GLE1 (Murphy & Wente, 1996) and GLE2
(Murphy et al., 1996). GLE1 has also been shown to interact with NUP100 in
the two-hybrid system and mutations of its NES result in nuclear accumulation
of poly (A)+ RNA (Murphy & Wente, 1996). Based on our results and those
presented above, one can envision Rev using its NES to interact with the GLFG
repeats of NUP100, and NUP100 using its NRM to interact with RREcontaining RNA being transported through the nuclear pore.

7. Sublocalization of NUP49 and NUP100 within the nuclear pore
complex

The locations of NUP100 or the NUP49 subcomplex within the nuclear
pore has not been determined. However, clues to NUP49’s location may be
seen in the mammalian p62 complex. p62 has been localized to the nuclear
and cytoplasmic peripheral regions of the central transporter area of the
nuclear pore complex (Guan et al., 1995; for review see Nigg, 1997). The p62
complex consists of p62 (putative homologue of NSP1), p54 (putative
homologue of NUP57) and p58/p45 (proteins derived by alternative splicing
and believed to be homologous to NUP49) (Guan et al., 1995; Hu et al., 1996;
for review see Doye & Hurt, 1997). NUP93, a human protein homologous to
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NIC96, may also bind to the p62 complex, but this is yet to be tested. It is
conceivable that NSP1 may be localized to regions similar to p62, and their
core complex members would be adjacent to them. However, in the absence
of ultrastructure electron microscope studies in yeast, this hypothesis remains
unproved (for review see Doye & Hurt, 1997).

8. A possible role for the nuclear pore in transcription

We were intrigued by the fact that we isolated the whole NUP49
encoding gene, unfused to the GAL4/AD, in the two-hybrid screen. It had
previously been shown that acidic regions of proteins fused to a BD could
function as transcriptional activators (Ruden et al., 1991).

We hypothesized

that the acidic NUP49 C-terminus containing the heptad repeats could function
as an acidic AD, and proved this hypothesis in two ways. First, cloning the
complete NUP49 gene into a yeast shuttle vector lacking the GAL4/AD allowed
Rev-dependent reporter transcriptional activation in the two-hybrid system.
Second, cloning the NUP100 GLFG domain, or the NUP49 GLFG domain, in
frame with a plasmid deleted for the GAL4/AD and replaced with NUP49 C
terminus, allowed Rev-dependent reporter transcriptional activation.
The ability of NUP49’s C-terminus to act as a transcriptional AD may
simply be charge mimicry of natural ADs.

However, another possibility is that

the nuclear pore contains regions that can bridge transcription of RNA with
transport. Some possible clues that support this latter hypothesis have been
found. Transcription factors have regions that interact with DNA, and regions
that activate transcription. NUP153, a nucleoporin located on the
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nucleoplasmic face of the nuclear pore complex has been shown to interact
with Rev’s NES in the two-hybrid system (Fritz & Green, 1996). This nucleoporin
contains zinc finger motifs that are known to bind rat genomic DNA in a zinc
dependent manner in vitro. It has been speculated that NUP153 may therefore
recognize a specific DNA motif, allowing for genes to be transcribed close to
the nuclear pore for subsequent transport (Sukegawa & Blobel, 1993).

p62’s

C-terminal domain containing heptad repeats was found to interact with the
transcription factor SP1. Antibodies to SP1 were found to co-precipitate p62,
and both proteins have been shown to interact with each other in the two-hybrid
system (Han et al., 1998). Nuclear lamina proteins located within the nuclear
envelope have been shown to use an RS domain to interact with p32 (Simos &
Georgatos, 1994; Nikolokaki et al., 1996), a protein known to interact with
splicing factors (Fu et al., 1992), demonstrating a possible link between factors
involved in RNA splicing and proteins at the nuclear envelope.

In light of these

additional results, it may be possible that NUP49’s ability to activate
transcription with it’s C-terminal heptad repeat region could have functional
relevance in vivo. Nucleopohns could interact with transcriptional complexes in
close proximity and be involved in transcriptional activation. The newly
transcribed RNA could then be directly transported though the nuclear pore.

9. Assaying for direct or indirect Rev-NUP interaction

Once we determined that the GLFG regions of both nucleopohns were
required for Rev interaction in the two-hybrid system, we were interested in
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testing whether these proteins had direct physical interactions with Rev. We
expressed and purified six-His tagged versions of NUP49 and the amino
terminus of NUP100, and used these purified proteins for in vitro mobility
supershift and ligand blot assays. In both sets of experiments Rev was not
found to interact directly with either of the nucleoporins. Other laboratories
subsequently reported the lack of a detectable direct interaction between Rev
and FG repeat containing nucleoporins, confirming our observations (Stutz et
al., 1996; Henderson & Percipalle, 1997).

These results taken together could

have meant that the interaction between these factors was weak, or that the
interaction was indirect and mediated by a cellular factor (s).
We sought to identify a potential bridging factor by using the reverse twohybrid assay. The full NUP49 protein was chosen as a bait in the screen for
several reasons. First, we reasoned that since it’s GLFG repeats interacted
with Rev in vivo probably through an indirect mechanism, a factor discovered
from the yeast genome that also interacted with this region may subsequently
be found to interact with Rev. Second, it might be possible to identify NES
containing factors homologous to Rev, that functioned in export. Third, we
sought to determine if factors involved in transcription could be found to interact
with the C-terminus of NUP49. Fourth, known nucleopore subcomplex
interacting partners of NUP49 might be isolated, allowing us to predict
NUP49’s status in the pore.
Two hundred and eighty six potential NUP49 interacting clones were
isolated out of *100,000 colonies screened. Two hundred and seventy eight of
these were proven to be false positives. The remaining eight by reason of
odds are most likely false positives as well. Three of the eight exhibited
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peculiar phenotypes. In the presence of the NUP49 plasmid they originally
activated the reporter gene LacZ. LacZ reporter activation was not detected
when these three clones were cured of the NUP49 plasmid and retested. This
result would be expected if a library factor was dependent on NUP49 for
reporter activation. However, when the NUP49 plasmid was retransformed into
these yeast cells, LacZ reporter activation was still not observed. We are
currently investigating this phenomenon further.
The detection of so many false positives in our assay was not
surprising, these results are expected when one screens a BD library as
opposed to a AD library, since 1% of the yeast genome codes for acidic
sequences that can function as transcriptional activation domains when fused
in frame to a BD (Stan Fields, personal communication). To reduce false
positives we utilized multiple replica plating steps (to test for NUP49
dependence), and a dual reporter strain under the control of dissimilar
promoters. In spite of our efforts this screen was unsuccessful in identifying a
true interacting Rev-NUP49 bridging factor.

10. CRM1 bridges the interaction between Rev and the nuclear pore
during nuclear export

In the process of analyzing the numerous false positives in our reverse
two-hybrid screen for a Rev-NUP49 bridging factor, our hypothesis of a bridging
protein was demonstrated by other laboratories.

We first became aware of

identification a Rev-NUP bridging factor, known as CRM1, at the 17th
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international congress of Biochemistry and Molecular Biology (Dirk Gorlich,
personal communication) in 1997 held in San Francisco, and subsequently
through publications that soon followed (Fornerod et al., 1997a; Fukuda et al.,
1997; Kudo et al., 1997; Neville et al., 1997; Ossareh-Nazari et al., 1997; Stade
et al., 1997; for review see Ullman et al., 1997).
There were a few clues to CRM1 being the potential bridging factor.
First, CRM1 was found to co-precipitate with the FG repeat portion of the
CAN/NUP214 nucleoporin (Fornerod et al., 1996; Fornerod et al., 1997b).
Second, CRM1 was determined to be localized in the nucleoplasm (Adachi &
Yanagida, 1989; Fornerod et al., 1997b) as well as at the cytoplasmic and
nucleoplasmic portions of the nuclear pore complex (Fornerod et al., 1997b).
This localization was found to be dynamic, in that nuclear expression of the
CAN/NUP214 repeat region depleted CRM1 from the nuclear pore complex and
relocalized it to the nucleoplasm (Fornerod et al., 1997b). Third, CRM1 showed
sequence homology with importin beta, a protein known to be involved in
docking transport cargo to the nuclear pore (Fornerod et al., 1997b). Fourth,
CRM1 mutations were found to confer resistance to the drug leptomycin B
(Nishi et al., 1994). This drug, whose target was determined to be CRM1, was
subsequently found to inhibit Rev-dependent mRNA export (Wolff et al., 1997).
These results implicated CRM1 as being a nucleocytoplasmic shuttling
protein, capable of direct interaction with FG repeats in the nuclear pore and
functionally important for Rev export.
CRM1 (chromosome region maintenance) is a 115 KD protein, originally
identified in a mutant search for genes that result in defects in chromosomal
superstructure (Adachi & Yanagida, 1989).

CRM1 is an essential gene in
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yeast (Toda et al., 1992). Human (Fornerod et al., 1997b) and Xenopus
(Fukuda et al., 1997) homologues have been identified. The CRM1 protein
product has been shown to interact with leucine rich Rev-like NES motifs
(Fornerod et al., 1997a; Neville et al., 1997; Ossareh-Nazari et al., 1997; Stade
et al., 1997) and RanGTP (Fornerod et al., 1997a; Stade et al., 1997) (the latter
protein is required for NES mediated export [Izaurralde et al., 1997; Richards et
al., 1997]) in a cooperative manner (Fornerod et al., 1997a). This cooperative
interaction is abrogated by NES mts (including Rev M10) and the drug
leptomycin B (Fornerod et al., 1997a; Ossareh-Nazari et al., 1997; Fukuda et al.,
1997). Overexpression of CRM1 in Xenopus oocytes enhances Rev RNA
transport function (Fornerod et al., 1997a). Mutations in the CRM1 gene in S.
cerevisiae decrease NES mediated export (Stade et al., 1997), as well as Revdependent RNA export (Neville et al., 1997). These results clearly show the
importance of CRM1 for Rev directed export.
In addition, CRM1 was found to interact with FG containing NUPs in the
two-hybrid system, including the GLFG nucleoporins NUP49, NUP57, and
NUP145 (Neville et al., 1997). Interestingly, the known interaction of Rev with
the yeast nucleopore protein RIP1 (originally isolated in a yeast two-hybrid
screen), was not detected in yeast mutated in the CRM1 gene. This result
supports the hypothesis that the interaction between Rev and nucleoporins in
the two-hybrid system is most likely indirect and mediated by a bridging
factor(s), one of which is now known to be CRM1. Only one group has
published a direct interaction between Rev and a nucleoporin-like protein RAB
(Bogerd et al., 1995). However, their results have been questioned due to the
possible presence of CRM1 in their experimental binding assays (Fornerod et
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al., 1997a). Based on the compilation of the above results CRM1 has been
determined be a carrier/receptor for leucine rich Rev-like nuclear export
signals, and it has been proposed that its name should be changed to
exportin 1 (Stade et al., 1997).

11. GLFG repeat containing nucleoporins may interact with Rev’s NLS
during nuclear import

Although in the two-hybrid system Rev-nucleoporin interaction was
shown to be mediated by its NES, and not by its NLS, this does not eliminate
the possibility that if these proteins were tested for interaction within the
cytoplasm, a positive result may have been obtained between Rev’s NLS and
the NUPs and not with Rev’s NES. Factors present within the nucleus
(CRM1/exportin 1) facilitate Rev’s interaction with the nucleoporins, and
therefore it may be possible that factors present within the cytoplasm (for ex.
importin beta) may facilitate interaction with the same repeat nucleoporins or
different ones through Rev’s NLS. Evidence in support of this hypothesis is the
involvement of NUP49 in import and export pathways (Doye et al., 1994). In
addition, Kap95 (importin beta homologue), in the presence of cytosolic extract,
has been shown to interact in vitro with GLFG nucleoporins NUP100, NUP116,
NUP145 (lovine et al., 1995; Aitchison et al., 1996), NUP49 and NUP57
(Aitchison et al., 1995). NLS substrate was also shown in vitro to be docked by
importin beta or its homologues to the GLFG nucleoporins NUP98 (Radu et al.,
1995a; Radu et al., 1995b), NUP100, NUP116, NUP145 (lovine et al., 1995)
and to the FXFG nucleoporins NUP214 (Radu et al., 1995a) and NUP153

147
(Radu et al., 1995a; Shah et al., 1998). Rev has been reported to use its NLS
to interact directly with importin beta, without importin alpha (Henderson &
Percipalle, 1997). Therefore Rev may be docked by importin beta to the above
nucleoporins during nuclear import, even though Rev has been reported to use
its NES to interact with the same noted NUPs (most likely through CRM1) in
two-hybrid experiments (Fritz & Green, 1996; Stutz et al., 1996; our unpublished
data).
Importin beta, CRM1/exportin 1 and a group of uncharacterized proteins
share a common CRIME domain (CRm1, IMportin p, Etcetera) (Fornerod et al.,
1997b). Further research into the function of this domain may determine that it
is used for interaction with a common factor. This factor could potentially be FG
repeat containing nucleoporins, Ran, or other potential unidentified common
binding proteins of importin beta and CRM1/exportin 1.

12. Summary

In summary, when this work was initiated it was believed that proteinprotein interaction was important for Rev function, however virtually nothing was
known about proteins that bound to Rev. Rev functions to transport RNA in
Xenopus oocytes (Fischer et al., 1995; Pasquinelli et al., 1997), yeast (Stutz &
Rosbash, 1994) and mammalian cells (Felber et al., 1989; Malim & Cullen,
1993). We therefore decided to use the two-hybrid system to search the yeast
genome for factors that could facilitate Rev function. Yeast was chosen
because it was a simpler system to study, and we felt that factors isolated
would have mammalian homologues. Rev was found to interact with two
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members of the GLFG family of yeast nucleopore proteins, NUP49 and
NUP100. We were one of the first groups to report this interaction. The Revinteracting region of NUP49 and NUP100 was localized to the amino-terminal
region of both nucleoporins containing their GLFG repeats. NUP49 and
NUP100 were found to interact with Rev’s nuclear export sequence, but not its
regions involved in RRE binding and nuclear localization, therefore implicating
the repeat regions of these nucleoporins as being involved in Rev nuclear
export.
Rev’s interaction with these nucleoporins could have been direct or
indirect. We investigated both of these possibilities. The nucleoporins were
expressed and purified as six-His tagged proteins, and were tested for a direct
interaction with Rev in vitro by mobility supershift and ligand blot assays.
However, a direct interaction was not detected. We therefore utilized a reverse
two-hybrid assay to investigate the alternative hypothesis, that Rev’s interaction
with the nuclear pore was indirect and involved one or more bridging proteins.
Problems inherent to this screen led to numerous false positives. While
sorting through these false positives, two findings were reported by other
groups. First, Rev was not found to interact with nuclear pore or nuclear pore
like proteins containing FG repeats in a direct manner, confirming our earlier
conclusions (Stutz et al., 1996; Henderson & Percipalle, 1997). Second, Rev
was found to interact with exportin 1 and RanGTP (Fornerod et al., 1997a;
Fukuda et al., 1997; Neville et al., 1997; Ossareh-Nazari et al., 1997; Stade et
al., 1997; for review see Ullman et al., 1997), these factors were determined to
be involved in bridging Rev’s interaction with the nuclear pore in vivo,
confirming our hypothesis that Rev’s interaction may have been indirect.
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B. Rev RNA protein interactions

1. Protein and RNA based anti-Rev therapeutics

A parallel project studying Rev’s interaction with RNA was undertaken to
facilitate our general understanding of Rev function. Multiple anti-Rev protein
and RNA therapeutic strategies have been attempted by several laboratories.
Transdominant versions of Rev (RevMIO) (Bevec et al., 1992; Bahner et al.,
1993; Woffendin et al., 1996; Bonyhadi et al., 1997) and elF-5A (Bevec et al.,
1996) have both been shown to inhibit Rev function and HIV-1 replication in
vivo. Anti-Rev RNA strategies including: antisense (Vandendriessche et al.,
1995), RRE/RBE decoys (Bevec et al., 1994; Bahner etal., 1996; Baureretal.,
1997; Inouye et al., 1997), ribozymes (Zhou et al., 1994; Michienzi et al., 1996;
Zhou et al., 1996) and dual RBE-ribozyme molecules (Yamada et al., 1996)
also have proven themselves effective in decreasing HIV-1 production by
blocking or decoying Rev action. For each of these agents to be effective in vivo
their mechanism of action must be specific for Rev. RBE aptamers obtained by
SELEX, were selected based on their higher affinity for Rev than the wild type
RBE (Giver et al., 1993a; Giver et al., 1993b; Tuerk & MacDougal-Waugh, 1993).
They can potentially serve as more potent Rev decoy molecules either alone or
in combination with ribozymes. In addition, a RBE aptamer linked to a ribozyme
may be able to colocalize a ribozyme to target HIV mRNA’s. We have
investigated the interaction of Rev with RBE aptamers alone or in combination
with ribozymes, and have determined that they are able to interact with high
specificity towards Rev. In addition we have developed a new method for
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transcribing functional RNA molecules in vitro. This method has the potential
for being used to produce RNAs in vivo, allowing for quick screening of optimal
anti-HIV antisense, ribozymes or RNA decoys.

2. Specific interaction of modified RBE aptamers 1 and 2 with
suc-Rev34-50-AAAAR-am peptide

RBE aptamers 1 and 2 (Symensma et al., 1996) were tested for their
specific interaction with a Rev basic domain peptide (suc-Rev34_50-AAAAR-am
peptide) using competition mobility shift assays. The Rev peptide was altered
to increase it’s alpha helical content, affinity and specific interaction with the
RBE (Tan et al., 1993). RBE aptamer 2 was found to interact specifically with
suc-Rev34_50-AAAAR-am peptide.

However, we were surprised at our initial

results that showed that RBE aptamer Ts interaction with Rev peptide was
nonspecific. This result was unexpected because the process of SELEX that
allowed for isolating these ligands is based on selecting high affinity, specific
interacting molecules. We reasoned that the minimal RNA aptamer
sequences we chose to synthesize, based on the published high affinity sites,
were not sufficient for stabilizing protein binding. RBE aptamer 2 (class I
aptamer) contained the sequences for two binding sites for Rev peptide, one
RBE-like motif, and another unique bulged U motif. While RBE aptamer 1
(class III aptamer) contained only the RBE-like motif (Giver et al., 1993a; Giver
et al., 1993b; Symensma et al., 1996). Originally, we thought that two base
pairs beneath both aptamers RBE-like motif would be sufficient for allowing
this internal loop structure to form. However, we realized that a possible
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explanation for our unusual results might be that if both RBE-like motifs were
not forming, then aptamer 1 would show nonspecific interaction, but aptamer 2
would still be able to interact specifically due to it’s bulged U motif. We tested
this possibility by utilizing Michael Zuker’s computer based RNA folding
analysis on the aptamer sequences with subsequent Loop-D-Loop computer
visualization. As suspected we found that both RBE-like motifs were not
predicted to form, while aptamer 2’s bulged U motif was predicted to be stable.
Based on our findings we chose to make modifications in the aptamers
that would stabilize their overall structures as well as their RBE-like motifs.
Aptamer 1’s loop region was changed from a tri-nucleotide to a tetra-nucleotide
loop. Thus, we added a sequence known to form a stable loop (Antao et al.,
1991; Varani et al., 1991), which should also stabilize the stem region below it.
In addition three base pairs were removed from below the tetra-nucleotide loop
of aptamer 1 and regions based on stem loop 2A of the wild type RRE (three
canonical and one non-canonical base pair) were added below it’s RBE-like
motif. Modifications of aptamer 2 included only the latter additions of stem loop
2A RNA based sequences below it’s RBE-like motif. Subsequent testing of
these aptamers in competition mobility shift assays showed that both
aptamers now were able to interact in a specific manner with the Rev peptide.
These results are consistent with studies attempting to define a minimal wild
type RBE sequence. Two base pairs below the RBE internal loop area gave
rise to a sequence that bound poorly to Rev, however addition of two additional
base pairs to this stem resulted in a high affinity, specific interaction between
Rev and the RBE (Bartel et al., 1991).
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3. Specific interaction of an RBE aptamer-ribozyme with Rev protein

Having shown that the aptamer molecules were able to interact
specifically with Rev peptide, we were interested in ascertaining whether
linking a ribozyme to an aptamer would affect the specificity of interaction of the
aptamer to Rev. To investigate this possibility, competition mobility shift
assays with Rev protein and a class 1 RBE aptamer-ribozyme were performed.
We found that Rev protein was indeed able to interact specifically with RBEaptamer 6a (Tuerk & MacDougal-Waugh, 1993; Jensen et al., 1994) linked to a
mutant envelope ribozyme. RBE-ribozyme molecules have been shown to
inhibit HIV-1 replication in vivo, potentially through a dual decoy-cleavage
mechanism. (Yamada et al., 1996). The inclusion of RBE aptamers, which are
known to interact significantly tighter with Rev (Giver et al., 1993a; Giver et al.,
1993b; Tuerk & MacDougal-Waugh, 1993; Symensma et al., 1996) in a dual
ribozyme molecule may prove to be a more potent decoy inhibitory agent. In
addition, interaction of Rev with these molecules might allow for them to be
transported to areas in the cell where other Rev bound mRNA’s are localized.
This colocalization could facilitate ribozyme cleavage. One possibility however
is that linking a highly structured ribozyme sequence to the aptamer may have
affected the aptamers ability to interact with Rev in a specific manner, we have
shown however that this is not the case.
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4. Novel templates for transcribing RNA

Towards the goal of developing a method for rapid in vitro and in vivo
transcription and screening of aptamers, ribozymes or antisense, we have
developed single DNA templates for T7 polymerase that transcribe functional
RNA in vitro and have the potential to produce functional RNA in vivo. 5’-5’
linkage of these single templates gives rise to a dual molecule, that produces
twice as much RNA as a single template in a bidirectional fashion (data not
shown). T7 polymerase is normally terminated by transcription of a stable
secondary structure that ends as run of U residues (Macdonald et al., 1993).
Incorporation of a sequence coding for a normal T7 terminator or a run of U’s
alone after our RNA molecule of interest would however lengthen our
templates, increasing their cost and potentially decreasing oligo yield. In
addition our preliminary results showed that these methods of termination
were inefficient in the context of our constructs (data not shown). Therefore we
chose to test a unique T7 polymerase transcriptional terminator. Propane diol
units included at the end of our RNA coding sequence were found to allow for
efficient termination and production of appropriately sized RNA molecules. We
hypothesize that the absence of a base in these units allows for the
polymerase to fall off the template. Aptamer 2, transcribed from a single
template and terminated with propane diol units, was found to show specific
interaction with Rev peptide in vitro using competition mobility shift assays,
showing that the RNAs produced from this template are functional. The
templates have been modified at their 3’ end with the addition of thiol residues
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to increase their cellular lifetime, further experiments will be necessary to test
their in vivo competence in RNA production and as screening tools.

C. Working model of Rev function
In the twelve years since the discovery of the HIV-1 Rev protein, a great
deal has been learned about Rev RNA and protein interactions and methods to
inhibit Rev function. Rev uses its NLS to enter into the nucleus (Kubota et al.,
1989; Malim et al., 1989b; Perkins et al., 1989; Venkatesh et al., 1990) (Fig. 26).
Proteins containing an NLS are translocated to the nucleus with help of
importin alpha (NLS receptor) and importin beta (docks substrate to the
nuclear pore) (Radu et al., 1995a; Rexach & Blobel, 1995; for reviews see
Pante & Aebi; Gorlich, 1997). However, Rev has been reported to be able to
interact directly with importin beta (at the importin alpha binding site)
(Henderson & Percipalle, 1997). B23 has been shown to interact with Rev’s
NLS (Szebeni et al., 1995), and has been reported to stimulate Rev import
(Szebeni et al., 1997). How B23 and importin beta work together in Rev import
has not been clearly defined but their importance has been shown. By analogy
with other import cargo, Rev should be docked to the nuclear pore allowing for
its transport. The import process requires free GTP and RanGDP. Once at the
nucleoplasmic side of the nuclear pore complex, RanGTP is necessary to
release import cargo into the nucleus (Gorlich et al., 1996; for reviews see
Koepp & Silver, 1996; Goldfarb, 1997; Gorlich, 1997) and Rev is know to
dissociate from B23 in the presence of the RRE (Fankhauser et al., 1991).
RanGTP then is essential for shuttling importin beta (Izaurralde et al., 1997; for
review see Gorlich, 1997) and most likely B23 to the cytoplasm.
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Once in the nucleus Rev needs to transport unspliced and singly-spliced
mRNA to the cytoplasm allowing for the translation of HIV structural and
accessory proteins. Rev interacts with p32 (Luo et al., 1994), a protein known
to coprecipitate with the alternative splicing factor ASF/SF2 (Krainer et al., 1990;
Krainer et al., 1991). ASF/SF2 has also been shown to interact with the RRE in
a Rev-dependent manner (Powell et al., 1997). These interactions may be
involved in inhibiting splicing thus allowing Rev to transport unspliced and
singly-spliced mRNA. Prothymosin alpha was shown to interact with Rev’s
NES, and it has been suggested that it may play a role in Rev export (Kubota et
al., 1995). elF-5A has been shown to stimulate Rev export, but the mechanism
of how this is accomplished is not understood (Bevec et al., 1996). RAB/Hrip is
a nucleoporin-like protein shown to interact with Rev’s NES and speculated to
be involved in bringing Rev to the nucleopore (Bogerd et al., 1995; Fritz et al.,
1995). CRM1/exportin 1 has been determined to be the NES receptor for Rev,
and is known to bind to Rev and RanGTP by a cooperative mechanism
(Fornerod et al., 1997a; Fukuda et al., 1997; Neville et al., 1997; OssarehNazari et al., 1997; Stade et al., 1997; for review see Ullman et al., 1997).
CRM1/exportin 1 interacts directly with FG repeat containing nucleoporins
(Fornerod et al., 1996; Fornerod et al., 1997b), and is believed to be involved
with bridging Rev’s interaction with FG repeat containing nucleoporins (Neville
et al., 1997). In yeast, we have shown that two nucleoporins of the GLFG class,
NUP49 and NUP100, interact with Rev’s NES most likely by an indirect
mechanism.

We now believe this interaction is mediated by CRM1/exportin 1.

CRM1/exportin 1 may therefore allow for Rev export by bridging interactions with
nucleoporins found at the nucleoplasmic, pore membrane, and cytoplasmic
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regions of the nucleopore complex. Once in the cytoplasm it has been
proposed that GTP hydrolysis allows for the release of the export cargo
(Fornerod et al., 1997a). Rev may transport HIV mRNA to the polysomes with
the help of elF-5A (Ruhl et a., 1993; Katahira et al., 1995), a protein shown to be
involved in initiating formation of the first peptide bond (Hershey et a., 1990).
Release of Rev from RNA would allow for its interaction with B23 and importin
beta giving rise to a new import cycle and repeated transport.
RNA molecules that interact with Rev and inhibit its ability to bind to the
RRE, and RNA molecules that bind Rev and facilitate transport of ribozymes to
HIV mRNA can serve as potential ways to inhibit HIV-1 replication in vivo.
Modified RBE aptamers 1 and 2 bind Rev with high specificity, and thus have
the potential to be very effective Rev decoys. RBE aptamer-ribozymes may be
able to act as dual inhibitory agents, cleaving HIV mRNA and decoying Rev
protein. In addition, these molecules potentially can use their interaction with
Rev to allow for their selective transport to areas of the cell where other Rev
bound HIV mRNAs are located. Novel templates terminated with propane diol
units have been shown to produce functional aptamers in vitro. These
templates have the potential to be used in vivo to screen for optimal RNA
aptamers, ribozymes, or antisense that inhibit HIV-1 replication.
D. Future directions
The interaction between Rev and nuclear pore proteins is presently
believed to be indirect and mediated by a cellular factor(s) (Fornerod et al.,
1997a; Fukuda et al., 1997; Neville et al., 1997; Ossareh-Nazari et al., 1997).
CRM1/Exportin 1 and RanGTP are two factors that have been implicating in
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bridging their interaction. A simple method to confirm CRMI’s importance for
the interaction we observed in the two-hybrid system between Rev and
NUP49/NUP100, will be to retest their interaction in the two-hybrid system
using a mutant CRM1 yeast strain. The absence of their interaction in the
mutant strain, coupled with the presence of positive controls known not to
involve CRM1 would clearly show CRMTs importance.
Although CRM1 has been shown to bind directly to repeat containing
nucleoporins (Fornerod et al., 1996; Fornerod et al., 1997b), and to Rev and
RanGTP cooperatively (Fornerod et al., 1997a), the actual complex of NUPCRM1-Rev-RanGTP has not been shown. NUP49 and NUP100 however
should be able to interact with CRM1 in a direct manner, this can be
determined by performing ligand blot assays with the individual components.
In addition, BIAcore experiments in which six-His tagged NUPs are
immobilized on sensor chip NTAs (Pharmacia), followed by injection of CRM1
containing samples over their surface can allow for quantification of
association/ dissociation constants, and determination of strength of NUPCRM1 binding. The ability of NUP-CRM1-Rev-Ran GTP complex to form in vitro
can also be determined with ligand blot assays. One possibility is that these
four components will not suffice for complex formation, therefore co
precipitation experiments may help to identify additional factors. Sepharose
bound six-His tagged NUP incubated with nuclear extract (spiked with the
potential complex components), may help to coprecipitate additional factors
necessary for interaction, thus facilitating cofactor identification. Potential
cofactors could also be isolated by using the two-hybrid system to screen for
NUP100 GLFG domain, or CRM1 interacting partners.

160
Our findings that the C-terminus of NUP49 can function as a
transcriptional AD was very intriguing. This interaction may be biologically
unimportant and purely due to charge mimicry of native ADs, or it could reflect
the ability of the nuclear pore to facilitate transcriptional activation. p62’s
interaction with the transcription factor SP1 using its heptad repeat region (Han
et al., 1998), suggests that the heptad repeat containing C-terminus of NUP49
may also interact with SP1. Coprecipitation and/or immunoprecipitation
experiments using nickel-NTA sepharose bound six-His tagged NUP49 (or its
C-terminal region) or antibodies to the six-His tag of NUP49 (or its C-terminal
region) could be used to determine the existence of an interaction between
SP1 and NUP49. The functional relevance of this interaction could be
determined by assaying the presence of synthetic lethality between mutations
in genes coding for both factors in yeast.
RBE aptamer 6a linked to a ribozyme was found to interact specifically
with Rev protein. This molecule can now be tested in vivo for the ability to
mediate Rev transport and colocalization. RBE aptamer 6a can interact with
two Rev molecules in vitro (data not shown), and results by Daly et al. (1993b)
suggest that two to three Rev proteins bound to the RRE are sufficient for
transport. In the case that two Rev molecules are not sufficient for transport,
the aptamer can be used to replace the RBE in stem-loop 2, and this modified
stem loop can be linked to the ribozyme and tested for transport. The
additional RNA regions of stem-loop 2 would allow for more Rev proteins to
bind, potentially aiding transport. Stem-loop 2 has also been shown to be
exported by Rev (Huang et al., 1991). Once an optimal RNA has been defined
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for transporting the linked ribozyme, ribozymes targeted to different essential
sites can then be assayed for the ability to colocalize and cleave HIV RNA.
RBE and RRE decoys have been shown to be effective methods for
inhibiting HIV (Bevec et al., 1994; Bahneret al., 1996; Baureretal., 1997; Inouye
et al., 1997). Aptamers selected to interact with higher affinity to Rev may
therefore prove to be more efficient antiviral agents. Modified RBE aptamer 1
and RBE aptamer 2 have been shown to interact with Rev peptide specifically.
They now will be tested (compared with the wild type RBE) for their ability to
inhibit HIV replication in vivo. In addition our collaborator Dr. Yuan Chen will be
conducting NMR experiments with the modified aptamers bound to Rev peptide
to learn more about the critical interactions, this effort is being undertaken in
hope of developing even stronger binding Rev binding RNA ligands.
We have shown that single templates for T7 polymerase can produce
RNA that is efficiently terminated by propane diol units in vitro. The RNA
produced has also been shown to be functional for specific protein interaction
in vitro. It can now be determined whether these single templates or dual
templates linked by their 5’ ends, can produce functional RNA in vivo. Also
experiments will be done to determine how stable these constructs are in a
cellular environment. Transfection of these constructs, coding for anti-HIV
aptamers, ribozymes, or antisense, into T7polymerase expressing cell lines
will be followed by Northerns or RT PCR analysis. If these RNAs are
expressed we can determine whether or not they are functional by HIV
challenge experiments. The strongest antivirals can be tested in combination,
to determine whether multiple inhibit better than single therapeutics. Genes
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coding for the most potent antiviral RNAs can be cloned into the necessary
vectors for further/'/? vivo testing against HIV infection.
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